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A B S T R A C T
Background
Intrauterine insemination (IUI) combined with ovarian hyperstimulation (OH) has been demonstrated to be an effective form of
treatment for subfertile couples. Several ovarian stimulation protocols combined with IUI have been proposed, but it is still not clear
which stimulation protocol and which dose is the most (cost-)effective.
Objectives
To evaluate ovarian stimulation protocols for intrauterine insemination for all indications.
Search methods
We searched for all publications which described randomised controlled trials comparing different ovarian stimulation protocols
followed by IUI . We searched the Menstrual Disorders and Subfertility Group’s Central register of Controlled Trials (CENTRAL) .
We searched the electronic databases of MEDLINE (January 1966 to present) and EMBASE (1980 to present).
Selection criteria
Randomised controlled trials only were considered for inclusion in this review. Trials comparing different ovarian stimulation protocols
combined with IUI were selected and reviewed in detail.
Data collection and analysis
Two independent review authors independently assess trial quality and extracted data.
Main results
Forty three trials involving 3957 women were included. There were 11 comparisons in this review. Pregnancy rates are reported here
since results of live birth rates were lacking.
Seven studies (n = 556) were pooled comparing gonadotrophins with anti-oestrogens showing significant higher pregnancy rates with
gonadotrophins (OR 1.8, 95% CI 1.2 to 2.7). Five studies (n = 313) compared anti-oestrogens with aromatase inhibitors reporting
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no significant difference (OR 1.2 95% CI 0.64 to 2.1). The same could be concluded comparing different types of gonadotrophins
(9 studies included, n = 576). Four studies (n = 415) reported that gonadotrophins alone are more effective than with the addition of
a GnRH agonist (OR 1.8 95% CI 1.1 to 3.0). Data of three studies (n = 299) showed no convincing evidence of adding a GnRH
antagonist to gonadotrophins (OR 1.5 95% CI 0.83 to 2.8). The results of two studies (n = 297) reported no evidence of benefit in
doubling the dose of gonadotrophins (OR 1.2 95% 0.67 to 1.9) although the multiple pregnancy rates and OHSS rates were increased.
For the remaining five comparisons only one or none studies were included.
Authors’ conclusions
Robust evidence is lacking but based on the available results gonadotrophins might be the most effective drugs when IUI is combined
with ovarian hyperstimulation. When gonadotrophins are applied it might be done on a daily basis. When gonadotrophins are used
for ovarian stimulation low dose protocols are advised since pregnancy rates do not differ from pregnancy rates which result from high
dose regimen, whereas the chances to encounter negative effects from ovarian stimulation such as multiples and OHSS are limited with
low dose gonadotrophins. Further research is needed for each comparison made.
P L A I N L A N G U A G E S U M M A R Y
Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility
Intrauterine insemination (IUI) is an assisted reproduction procedure that places spermdirectly into the uterus. Additionally,medication
(hormones) are given to hyper stimulate the ovaries, which results most of the time in the release of more eggs which can be fertilized
and this in turn, results in higher pregnancy rates, but also in a higher number of multiple pregnancies.
Forty three trials involving 3957 women were included. The review compared different drugs for ovarian hyperstimulation showing
that injections result in higher pregnancy rates compared with oral medication. However, the evidence for this result is not very strong.
Furthermore, it showed that if stimulation is used it might be done with low dose injections, since multiple pregnancy rates were
increased with high dose injections, without resulting in more pregnancies. This review does not show which injection should be used,
since there is no convincing evidence of a difference. Finally, this review does not answer the question whether the addition of GnRH
agonist or antagonist is useful.
B A C K G R O U N D
Worldwide, intrauterine insemination (IUI), is one of the most
frequently used fertility treatments for couples with unexplained
or male subfertility (Cohlen 2005; Goverde 2000). A systematic
review of randomised controlled trials (RCTs) comparing IUI with
timed intercourse reported a three fold increase in the probabil-
ity of conception with IUI for couples with persistent infertility
(Hughes 1997). IUI is often combined with ovarian hyperstimu-
lation (OH) to increase the number of available oocytes and there-
fore, to further enhance the probability of conception. The use of
OHmay also correct subtle cycle disorders and allows for optimal
timing of the insemination. The use of gonadotrophins to achieve
OH for IUI cycles has been shown to be an effective treatment
modality for couples with unexplained subfertility compared with
IUI in natural cycles (OR 2.4, 95%CI 1.4 to 3.9) (Hughes 1997).
A more recent systematic review suggests that ovarian stimulation
and IUI is more likely to result in a live birth than IUI in nat-
ural cycles (OR 2.0, 95% CI 2.0 to 3.5) (Verhulst 2006). For
severe male subfertility (total motile sperm count < 10 million)
IUI is more effective compared with timed intercourse, although
the benefit of additional ovarian stimulation in these couples has
not been proven. On the other hand, OH does seem to improve
pregnancy rates in couples with a mild semen defect (total motile
sperm count > 10 million) (Cohlen 1997). Mild endometriosis
in women with no other cause of infertility is often considered
to be comparable to unexplained infertility and in these couples
stimulated IUI has been recommended although it is uncertain
whether or not un stimulated IUI may also be beneficial (NICE
Guidelines 2004).
However,OH is associated with an increased risk of multiple preg-
nancies, which in turn increases maternal risks, preterm delivery
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and perinatal morbidity and mortality. Increasingly, trialists are
being encouraged to report BESST (Birth Emphasizing a Success-
ful Singleton at Term) as the primary outcome (Min 2004). Bear-
ing this in mind, it is important that protocols for IUI in combi-
nation with OH seek to keep multiple pregnancies to a minimum
(Cohlen 2005). Anothermajor adverse event with gonadotrophins
is the probability of achieving ovarian hyperstimulation syndrome
(OHSS) (Derman 1994). Adverse effects to consider with oral
ovarian stimulation protocols are: hot flushes, visual disturbances,
anti-oestrogenic effects on the endometrium and cervical mucus.
The benefits of oral ovarian stimulation agents are their conve-
nience and their low cost, although it has been suggested that they
are less effective for IUI (Hughes 1997;s Cohlen 1997). Several
RCTs have been published that compared oral versus injection
agents, but most of them lack sufficient power to draw firm con-
clusions (Athaullah 2002). Recently, a new oral drug has been
added to the armamentarium of ovarian stimulating drugs: aro-
matase-inhibitors. Gonadotrophin releasing hormone analogues
(GnRH-analogue) have also been used in protocols for ovarian
stimulation. More recently, gonadotrophin releasing hormone an-
tagonists (GnRH antagonist) have been proposed in IUI programs
as an alternative to GnRH agonists (Ragni 2004).
Finally, various dosages of ovarian stimulation agents are being
used in order to optimise pregnancy rates, while reducing the
number of multiple pregnancies. For example, 150 IU of follicle
stimulating hormone (FSH) was associated with a multiple preg-
nancy rate of 27% (Guzick 1999), whereas other studies that used
a lower dose of FSH (50-75 IU) reported singleton pregnancies
only (Balasch 1994; Ragni 2004).
In conclusion, the optimal ovarian stimulation protocol should
maximise the probability of conception (ideally expressed as sin-
gleton live birth at term) and in the mean time minimise the risk
of multiple pregnancies and the occurrence of OHSS.
O B J E C T I V E S
To evaluate ovarian stimulation protocols preceding intrauterine
insemination in couples with various causes of subfertility (e.g.
unexplained subfertility, male factor subfertility and endometrio-
sis).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials only were considered for inclusion
in this review. Trials with a cross-over design were included only
in the analysis if first cycle data were available. Quasi-randomised
controlled trials were excluded.
Types of participants
Couples who have been trying to conceive for at least one year
and for whom OH combined with IUI is a treatment option,
including:
- Unexplained subfertility which was defined as a subfertility of at
least one year duration without any abnormality found at routine
fertility investigation (consisting of the following: ovulatory status
confirmed with biphasic basal body temperature chart (BBTC),
luteal progesterone (P) or sonographic evidence of ovulation; tubal
patency confirmed; normal semen parameters as defined by the
WHO).
- Male factor subfertility was defined as semen quality not meet-
ing the criteria for normality as defined by the World Health Or-
ganization (WHO) in 1987 (thus at least): sperm concentration
< 20 x 106/ml or total motility < 50% or normal morphology
< 50%, < 14% normal morphology was considered as abnormal
when Kruger criteria were used (Kruger 1993). In 1992 theWHO
changed its criteria for sperm morphology from 50% to 30%
(WHO 1992).
- Mild endometriosis was diagnosed by laparoscopy.
-Other types of subfertilitywhichwere treatedwithOHcombined
with IUI.
Types of interventions
IUI with ovarian hyperstimulation, where OH is the same as ovar-
ian stimulation also defined as controlled ovarian hyperstimula-
tion (COH). However, ’controlled stimulation’ of the ovaries sug-
gests that some form of control can be performed, which is not
the case.
1. Anti-oestrogens versus gonadotrophins
2. Anti-oestrogens versus gonadotrophins with GnRH agonists.
3. Anti-oestrogens versus gonadotrophins with GnRH antago-
nists.
4. Anti-oestrogens versus aromatase inhibitors.
5.Gonadotrophins alone versus gonadotrophins alone for example
FSH versus HMG and u-FSH versus r-FSH.
6. Gonadotrophins alone versus gonadotrophins with GnRH ag-
onists.
7. Gonadotrophins alone versus gonadotrophins with GnRH an-
tagonists.
8. Gonadotrophins alone versus gonadotrophins with anti-estro-
gens.
9. Different dosage regimens for anti-oestrogens or aromatase in-
hibitors.
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10. Different dosage regimens for gonadotrophins (High dose
(>75 IU per day) versus low dose gonadotrophins (75 IU or less
per day)).
11. Other comparisons
Studies which compared stimulated IUI with IUI in natural cycles
were excluded as this is the topic of other reviews (Cohlen 2000;
Verhulst 2006).
Types of outcome measures
Primary outcomes
- Incidence of live births (live birth rate/couple) and incidence
of pregnancies beyond 12 weeks (ongoing pregnancy rate/couple)
when live births are not mentioned
- Incidence of multiple pregnancies beyond 12 weeks (multiple
pregnancy rate/couple)
Secondary outcomes
- Incidence of miscarriages (miscarriages/ couple and per preg-
nancy)
- Incidence of ovarian hyperstimulation syndrome (OHSS)
(OHSS/ couple)
- Incidence of ectopic pregnancy (ectopic pregnancy per couple
and per pregnancy)
Search methods for identification of studies
We searched for all publications which described (or might de-
scribe) RCTs comparing different stimulation protocols followed
by IUI.
(1) We searched the Menstrual Disorders and Subfertility Group’s
Central register of Controlled Trials (CENTRAL) .
(2) We searched the electronic databases of MEDLINE (January
1966 to present) and EMBASE (1988 to present) through Science
Direct.
We searched these databases using the Cochrane search strings for
RCTs and the following subject headings and keywords:
intrauterine; intra uterine; intra-uterine; insemination; IUI; arti-
ficial insemination; AIH; mild ovarian hyperstimulation; MOH;
controlled ovarian hyperstimulation; COH; hyperstimulation;
ovarian stimulation; clomiphene citrate;CC; anti-oestrogens;Clo-
mid; Serophene; aromatase inhibitors; letrozole; follicle stimu-
lating hormone; FSH; recFSH; u-FSH; gonadotropins; human
menopausal gonadotropins; hMG; highly purified FSH; urinary
FSH; Menopur; humegon; menogon; pergonal; Gonal-f; Pure-
gon; Ganirelix; GnRH; GnRH-analogue; LHRH; LHRH ana-
logue; LHRH-analogue; GnRH-antagonist; Cetrorelix; Cetrotide
(3) We handsearched the reference lists of all identified and in-
cluded studies.
(4) We handsearched abstracts of the American Society for Repro-
ductive Medicine (1987 to 2005) and the European Society for
Human Reproduction and Embryology (1987 to 2005) meetings.
If important information is missing from the original publications
we tried to contact the authors using different means of commu-
nication and sent them a reminder a couple of weeks later. We did
not restrict the search by language.
Data collection and analysis
Two review authors (AEPC,MJH) independently selected the tri-
als included according to the aforementioned criteria. Disagree-
ments were resolved through arbitration by BJ Cohlen. Analysis of
agreement between the two observers for inclusion was performed
using crude percentage agreement. This analysis was performed
on themethod of randomisation, concealment of allocation, study
design and primary outcomes. Type of study, quality of the se-
lected studies, type of participants, type of interventions and type
of outcome measures mentioned at the ’criteria for considering
studies’ section were extracted and assessed by these same two ob-
servers as were the data. If specific information was missing, we
contacted one of the trial authors by letter, email or fax.
Quality assessment
We extracted the following characteristics from each trial to assess
the quality of included studies.
- Method of randomisation; adequately randomised, quasi- ran-
domised or not clear.
Quasi-randomised: e.g. trials using alternating record numbers,
dates of birth or odds and even numbers will not be included.
Studies where the method of randomisation is not clear: e.g. not
stated or stated without further description will be included in the
review.
- Concealment of allocation; adequate, inadequate or not clear.
Adequate allocation: e.g. by third party or sealed opaque envelopes.
Inadequate allocation: e.g. open list of random numbers or open
envelopes/ tables. Not clear: e.g. not stated or stated without fur-
ther description.
- Trial design; parallel design, cross-over design or not clear.
Parallel designed studies or first data of cross-over studies will be
included.
- Power calculation; power calculation beforehand, no power cal-
culation or not clear.
-Drop-outs; details andnumber of dropouts (couples) or nodetails
on dropouts.
- Cancelled cycles: reason for and number of cancelled cycles given
or no details on cancelled cycles given.
- Blinding; when possible and appropriate blinding will be as-
sessed.
- Intention to treat analysis: performed, not performed or not
clear.
Data extraction
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We extracted the following characteristics of the participants from
each trial to define the type of participants in detail and to detect
possible clinical heterogeneity:
- Age of the woman;
- Duration of subfertility;
- Type of subfertility;
- Previous fertility treatments;
- Primary or secondary subfertility.
We extracted interventions which might have influenced treat-
ment outcome were extracted from each study as well. The fol-
lowing interventions were considered:
- Dosage of medication for ovarian stimulation
- Trigger for ovulation (endogenous LH surge, hCG);
- Timing of insemination;
- Single or double insemination per cycle (Cantineau 2002);
- Semen preparation technique (Boomsma 2004);
- Number of motile sperm injected;
- Donor semen or husband/partner semen;
- Type of insemination device/ catheter;
- Cancel criteria.
We extracted the following outcomes were extracted from each
study when possible:
- Live births and pregnancies beyond 12 weeks;




The outcomes ’costs of treatment’, ’international units (IU) used
(when applicable)’ and ’number of dominant follicles’ were re-
ported in the original protocol, however these were not stated in
the final review since we concluded they were of no relevance and
making the review too complicated.
Statistical analysis
We performed statistical analyses in accordance with the guide-
lines for statistical analysis developed by the Cochrane Menstrual
Disorders and Subfertility group (MDSG).
For dichotomous data, the results for each study were expressed
if appropriate as odds ratios (OR) with 95% confidence inter-
vals (CI) and combined for meta-analysis with RevMan software.
Continuous data were combined for meta-analysis with RevMan
software using the weighted mean difference (WMD) with 95%
CI.
Heterogeneity between the results of different studies was noted
when the confidence intervals did not overlap. This was checked
by the results of Chi-squared tests and the I-squared (I2) statis-
tic for inconsistency. The cut-off levels we used were: I2 below
30% a fixed-effect model should be used and a I2 above 60% a
random-effect model should be used. Between 30 and 60% the
choice of model was based on differences of the studies included.
If high quality RCTs were included with comparable patients, the
fixed-effect model was used. When statistical heterogeneity was
presumed, the random-effect model results were reported as well.
Then, the trials were re-studied to detect clinical heterogeneity
which was taken into account.
Publication bias was investigated by constructing a funnel graph,
plotting sample size versus effect size. A funnel plot was not con-
structed when insufficient studies were available.
The outcome of live birth rates and pregnancy rates was consid-
ered a positive consequence of treatment therefore a higher pro-
portion of women with a live birth or a pregnancy was considered
a benefit. For adverse outcomes such as multiple pregnancy rate,
miscarriage rate and OHSS rate which are negative consequences,
higher numbers were considered to be detrimental (increased odds
signifies relative harm). This needs to be taken into consideration
when the meta-analyses are viewed.
A priori a subgroup analysis was described for trials comparing
two different stimulation protocols in couples with different types
of subfertility. Enough studies had to be included (at least two) to
make meta-analyses of subgroups possible.
A priori it was also planned to perform sensitivity analyses if there
are more than five trials included in the review to examine stability
regarding the direction of outcomes.
It is the intention of the review authors that a new search for
RCTs will be performed every two years and the review updated
accordingly.
R E S U L T S
Description of studies
With the adopted search strategy we were able to retrieve 81 trials.
We analysed these trials in detail.
Analysis of agreement between the two observers for inclusion was
performed using crude agreement, which occurred for 75 of the
81 trials (93%). After discussion consensus was reached regarding
all trials. Of the included trials agreement concerning whether
an adequate comparison was made occurred in 98% of the trials.
Agreement on the method of randomisation was reached in all
cases.
Also See Table 1
Excluded studies
Reviewing the retrieved trials resulted in exclusion of 31 trials for
the following reasons: they either did not perform a comparison
of interest (n=7) (Arcaini 1996; Doyle 1991; Jaroudi 1998;Nappi
2000; Papageorgiou 1995; Steinkampf 1993;Tummon 1997) or
failed to use an adequately randomised design (n=23) (Allegra
1990 I; Allegra 1990 II; Alvarez 1999; Brami 2004; Chang
1993; Check 1992; Crosignani 2005; DiMarzo 1992; Isaza 2000;
Isaza 2003; Jacobson 1991; Manganiello 1997; Mitwally 2002;
Mitwally 2003 I;Mitwally 2003 II;Mitwally 2004;Mitwally 2005;
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Nava 2004;Nuojua-Huttunen 1997; Prentice 1995; Ruddock
2004; Taskin 2005; Vasiljevic 2000). The abstract of Matorras
(1999) was excluded since the full text publication of 2000 con-
tained the same data (see table ’Characteristics of excluded stud-
ies’).
Seven studies are awaiting further assessment for the follow-
ing reasons: 1. Timed intercourse or DIPI was applied in cer-
tain cycles and cycles could not be separated (n=4) (Bekuretsion
1999; Fernandez 2001; Karlstrom 2000; Karlstrom 2002); 2. It
is questionable whether the trial was adequately randomised (n=
3) (Colombi 1996; Karande 1995;Kotecki 2005);(see also table
’Characteristics of studies awaiting assessment’).
Attempts were made to contact the authors by e-mail or letter or
both to provide us with details that were not reported and further
information about the published data. Five replies have been re-
ceived as of November 2006hich resulted in exclusion of two pub-
lications (Isaza 2000; Matorras 1999) and inclusion of the correct
data for one publication (Karlstrom 1993). Two authors provided
additional information about several publications included (Gerli
and Filicori).
Included studies
The remaining 43 studies were eligible for inclusion in this sys-
tematic review. These trials comprised 3957 women. The total
number of treatment cycles was not exactly known because five
trials (Demirol 2002;El Helw 2002;Fatemi 2003;Sammour 2001;
Unfer 2004) did not mention their number.
Twenty-nine trials presented data that could be pooled in one of the
meta-analyses, while the other eight studies could not be pooled
for various reasons; they did not provide information about live
births or pregnancy rate per couple, although one of these studies
(Nakajima 1999) provided data on secondary outcomes (see table
’Characteristics of included studies’), or it was not possible to
derive the correct information from their reports, and we have not
received adequate response from requests for the required values
through email or letter. This made it impossible to include these
studies in themeta-analyses according to theReviewers’Handbook
(Higgins 2005). Furthermore, the results of one cross-over study
were not pooled as first cycle data was lacking (Dodson 1991).
The remaining five trials compared ovarian stimulation protocols
which we did not define beforehand (such as aromatase inhibitors
versus gonadotrophins). Subgroup analyses were not performed
since each of these studies compared other interventions (Gerli
2000;Jamal 2005; Kim 1996; Unfer 2004;Wang 2004).
Pregnancy was confirmed mostly by ultrasound after 7 weeks and
ongoing pregnancy with a second ultrasound after 12 weeks of
pregnancy.
We will describe the studies in detail for each comparison sepa-
rately.
1. Anti-oestrogens versus gonadotrophins
Seven of the eight trials included for this comparison reported the
number of women in each treatment arm, including 556 women
in total. Three trials (Kamel 1995; Karlstrom 1998; Nakajima
1999) were published as abstracts only.
Type of participants
All except one study (n = 7) (Balasch 1994; Dankert 2006;
Ecochard 2000; Kamel 1995; Karlstrom 1993; Karlstrom 1998;
Nakajima 1999) included couples diagnosed with unexplained
subfertility or mild male factor subfertility or both. The study of
Matorras 2002 included couples diagnosed with severemale factor
and as a result donor sperm was used for intrauterine insemina-
tion.
Three studies (Ecochard 2000; Karlstrom 1993; Karlstrom 1998)
included also other types of subfertility such as endometriosis,
ovarian dysfunction and cervical factor.
The reported diagnostic investigations differed among the tri-
als. Five studies (Balasch 1994; Dankert 2006; Ecochard 2000;
Karlstrom1993;Matorras 2002) reported a complete investigative
work-up consisting of most of the following tests: semen-analysis,
basal body temperature chart (not reported by Matorras 2002),
hormone essays (not reported by Dankert 2006 and Ecochard
2000), post-coital testing (not reported by Matorras 2002), hys-
terosalpingography, endometrial biopsy (not reported by Dankert
2006 and Karlstrom 1993) and diagnostic laparoscopy. The re-
maining trials were published as abstracts and stated that complete
investigation was done or did not state details about diagnostic
investigations.
The age of women was stated in five trials (Balasch 1994; Dankert
2006; Ecochard 2000; Karlstrom 1993; Matorras 2002). The
mean age in the anti-oestrogen group was 31.2 ± 3.1 years com-
pared to 31.5 ± 3.5 years in the gonadotrophin group. The same
trials reported themean duration of subfertility: 4.3 ± 2.6 years for
the anti-oestrogen group and 4.2 ± 2.4 years for the gonadotrophin
group.
Three of the studies included (Dankert 2006; Karlstrom 1993;
Matorras 2002) reported that none of the included couples un-
derwent previous fertility treatment. Two studies (Dankert 2006;
Matorras 2002) reported the percentage of primary infertility
which was 100% and 94% respectively.
Type of interventions
Trials comparing clomiphene citrate with gonadotrophins used 50
or 100mgCCper day for five days and 75 to 150 IU hMGor FSH
per day.When 50 mgCCwas used for five days this was compared
with 75 IU FSH from cycle day 3 to day 7 (Balasch 1994; Kamel
1995). The studies that used 100mgCCcompared this with 75 IU
rFSH (Dankert 2006) or 150 IU uFSH or hMG (Karlstrom 1993;
Karlstrom 1998; Matorras 2002). Only Ecochard and co-workers
used an alternate day scheme for the use of gonadotrophins.
All studies included comparing anti-oestrogens with go-
nadotrophins used 5000 IU (Dankert 2006; Ecochard 2000;
Matorras 2002) or 10.000 IU (Balasch 1994; Kamel 1995;
Karlstrom 1993; Karlstrom 1998) hCG. Three studies (Ecochard
2000; Karlstrom 1998; Nakajima 1999) used also LH determina-
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tion in urine or blood to adjust timing in cases of an LH surge.
In the studies using hCG only for timing, one insemination was
performed between 35 and 42 hours after hCG injection. Studies
that used LH determination as well, reported a wider interval
for insemination from 24 hours after LH determination until 38
hours when no surge was detected. It is questionable whether
anticipating on such an unexpected (premature) LH surge results
in favourable outcomes (Cohlen 1998).
The five studies (Balasch 1994; Dankert 2006; Ecochard 2000;
Karlstrom 1993; Matorras 2002) which were full publications re-
ported four different semenpreparation techniques; swim-up tech-
nique, Percoll gradient technique, self-migration with hyaluronic
acid and Puresperm respectively. Up until now there is insufficient
evidence to recommend any specific preparation technique, due to
a lack of large high quality randomised controlled trials, compar-
ing the effectiveness of a gradient or a swim-up or wash and cen-
trifugation technique or all three on clinical outcome (Boomsma
2004).
All trials performed one intrauterine insemination only.
Two studies (Balasch 1994 and Karlstrom 1993) reported the
number of inseminatedmotile sperm for conceptual and non-con-
ceptual cycles, which were comparable in both trials. The number
of inseminatedmotile spermwas reported in three studies (Balasch
1994; Kamel 1995; Karlstrom 1993), and none reported a note-
worthy difference between both treatment groups.
In one study (Matorras 2002) donor semen was used. This study
included subfertile couples with severe male subfertility or other
indications for usingdonor semen.All other studiesmentioned the
use of husband semen or the context made clear husband semen
was used.
Three studies (Balasch 1994; Karlstrom 1993; Matorras 2002) re-
ported the type of insemination catheter used. Balasch and co-
workers used the IUI catheter in their study, Karlstrom used in his
study of 1993 the Kremer catheter or the TDT catheter for insem-
ination and Matorras and co-workers used the Frydman catheter
in their study of 2002.
Three studies (Dankert 2006; Ecochard 2000; Matorras 2002)
reported cycle cancellation criteria to prevent adverse outcomes,
such as multiple pregnancies and OHSS. The first study cancelled
cycles when more than three follicles were 14 mm. The second
study used the same criteria adding that cycles were cancelled
as well when E2 levels exceeded 1200 pg/ml. The third study
(Matorras 2002) cancelled when more than six follicles were 15
mm or more or E2 levels exceeded 2000 pg/ml.
Type of outcomes
One (Dankert 2006) of the eight studies included comparing anti-
oestrogens with gonadotrophins reported live birth rates. All ex-
pect one study (Nakajima 1999) reported pregnancy rates per cou-
ple. One of these studies (Balasch 1994) reported ongoing preg-
nancy rates per couple as well. Pregnancy was confirmed by ul-
trasound after seven weeks and ongoing pregnancy with a second
ultrasound after 12 weeks of pregnancy.
Multiple pregnancy rates and miscarriage rates were stated in
four publications (Balasch 1994; Dankert 2006; Matorras 2002;
Nakajima 1999) and the OHSS rate was stated in two publica-
tions (Balasch 1994;Matorras 2002).None of the studies reported
ectopic pregnancies.
2. Anti-oestrogens versus gonadotrophins with GnRH agonist
None of the studies included compared anti-oestrogens with go-
nadotrophins combined with a GnRH agonist.
3. Anti-oestrogens versus gonadotrophins with GnRH antago-
nist
None of the studies included compared anti-oestrogens with go-
nadotrophins combined with a GnRH antagonist.
4. Anti-oestrogens versus aromatase inhibitors
Five studies included (Al-Fozan 2004; ElHelw2002; Fatemi 2003;
Ozmen 2005; Sammour 2001) compared anti-oestrogens with
aromatase inhibitors. Three studies (El Helw 2002; Ozmen 2005;
Sammour 2001) were published as abstract of congress meetings
only. In total results of 313 couples were pooled.
Type of participants
All studies included couples diagnosed with unexplained subfer-
tility. One study (Ozmen 2005) included mild-moderate male in-
fertility as well.
The reported inclusion criteria varied among these studies. While
Al-Fozan and co-workers reported that patients were included if
patent tubes were seen on hysterosalpingogram and the semen
analysis was normal, Fatemi and co-workers stated more criteria:
age below 39 years, body mass index between 18 and 29 kg/m2,
presence of ovulatory cycles with duration between 24 to 35 days,
FSH concentrations on day 3, normal liver and kidney function,
negative history for tubal pathology and normal semen analysis.
The three remaining publications (all abstracts) (El Helw 2002;
Ozmen 2005; Sammour 2001) did not state inclusion criteria and
no further defined unexplained or male factor subfertility.
The age of women was stated in three trials (Al-Fozan 2004;
Fatemi 2003; Sammour 2001). Themean age in the anti-oestrogen
group was 30.8 ± 0.5 years compared to 30.1 ± 0.5 years in the
aromatase inhibitors group. Two trials (Al-Fozan 2004; Sammour
2001) reported the mean duration of subfertility per treatment
group: 2.5 ± 0.3 years for the anti-oestrogen group and 2.4 ± 0.2
years for the aromatase-inhibitors group.
None of the studies reported whether included couples underwent
previous fertility treatment. Only the full text publications (Al-
Fozan 2004;Fatemi 2003) reported that couples with secondary
infertility were included as well.
Type of interventions
Both types of drugs were given for five days consecutive in each
study, except in one (El Helw 2002) where a single dose of 20 mg
of aromatase inhibitor was compared with anti-oestrogens given
for five days. The daily dose of aromatase-inhibitors varied among
the trials from 2.5 to 7.5 mg; two studies (Fatemi 2003; Sammour
2001) compared 2.5mg letrozole with 100mg clomiphene citrate.
Ozmen and co-workers compared 5 mg letrozole with 100 mg
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clomiphene citrate and Al-Fozan 2004 compared 7.5 mg letrozole
with 100 mg clomiphene citrate.
Four studies (Al-Fozan 2004; El Helw 2002; Ozmen 2005;
Sammour 2001) used hCG to time insemination. Two of these
studies (Al-Fozan 2004; Sammour 2001) timed insemination
twice; 24 and 48 hours after hCG injection, whereas the other
two studies (El Helw 2002; Ozmen 2005) timed insemination
once after 33-36 hours. The fifth included study of Fatemi and
co-workers (2003) timed the insemination 24 hours after the en-
dogenous LH surge. This surge was defined as LH concentrations
three times higher than the concentration observed in the previous
24 hours.
One study (Ozmen 2005) only reported the type of semen prepa-
rationusing a density gradient.None of the studies stated explicitly
that the husband’s semen was used. However, all studies included
couples with unexplained subfertility which makes it illogical that
they used donor semen. Two studies (El Helw 2002; Sammour
2001) mentioned that no difference was found between the two
groups in semen characteristics, but none of the studies reported
the number of motile sperm inseminated.
None of the studies stated the type of insemination catheter used,
nor cancellation criteria for preventing multiples.
Type of outcomes
None of the studies included reported live birth rates, but they
reported pregnancy rates per couple instead. Ongoing pregnancy
rates were reported in two studies (Al-Fozan 2004;Fatemi 2003),
butwithout reporting the definitionof anongoing pregnancy.One
study (Al-Fozan 2004) reported secondary outcomes (multiple
pregnancies, miscarriages and ectopic pregnancies).
5. Gonadotrophins versus gonadotrophins
Two comparisonswere created both comparing two different types
of gonadotrophins: A. hMG versus r-FSH and B. r-FSH versus
u-FSH. Three studies (Filicori 2001; Filicori 2003; Gerli 1993)
compared hMG with r-FSH including 132 couples in total. Four
studies (Gerli 2004; Gerli 2004 II; Matorras 2000; Pares 2002)
compared r-FSH with u-FSH including 444 couples in total. The
two remaining studies (Demirol 2002; Gurgan 2004) both com-
pared more than two different types of gonadotrophins. Demirol
and co-workers compared hMG with u-FSH and two different r-
FSH. Description of this comparison is stated under C. Finally,
Gurgan and co-workers compared hMG with u-FSH and r-FSH
including 241couples in total. Description of this study is stated
under D.
Two publications (Demirol 2002; Gurgan 2004) were published
as abstracts only.
A. hMG versus r-FSH:
Type of participants
Both studies of Filicori and co-workers included couples with un-
explained or mild male factor subfertility. The remaining study
(Gerli 1993) included couples with unexplained subfertility only.
Type of subfertility was not defined explicitly in one of the three
studies, but inclusion criteria consisted of: no ovulatory dysfunc-
tion, a body mass index between 17 to 25 kg/m2, a pelvic ultra-
sound showing normal uterus and ovaries, hysterosalpingogram
and/or laparoscopy demonstrating tubal patency and normal hor-
mone analysis in the studies of Filicori and co-workers. The study
of Gerli and co-workers reported inclusion criteria as no ovulatory
dysfunction, tubal or uterine factor, or male factor or both.
The age of women included was stated in all three trials. The mean
age in the FSH group was 31.6 ± 1.5 years compared to 32.3 ± 1.7
years in the hMGgroup. One trial (Gerli 1993) reported themean
duration of subfertility per treatment group: 2.3 ± 0.6 years for the
FSH group and 2.6 ± 0.8 years for the hMGgroup. Filicori and co-
workers mentioned in both publications that some of the women
included had received ovulation induction previously, but not for
at least three months preceding the study. Gerli and co-workers
did not state whether previous fertility treatment was given. None
of the studies reported primary or secondary subfertility.
Type of interventions
Both studies of Filicori and co-workers used 150 IU go-
nadotrophins in both treatment arms and the third study (Gerli
1993) used 225 IU FSH or hMG. All studies applied a single dose
of LHRH agonist in the preceding luteal phase.
All studies (Filicori 2001; Filicori 2003; Gerli 1993) used hCG
to time insemination. In both studies Filicori and co-workers per-
formed a single insemination 36 hours after 10.000 IUhCG.Gerli
and co-workers performed two inseminations, one 12 hours and
one 36 hours after 5000 IU hCG.
All studies used a swim-up technique for semen preparation. Of
the three studies one study (Filicori 2003) stated explicitly that
partners’ semen was used, but it is likely that the other two studies
used partners’ semen as well. The second study of Filicori 2003,
also found no difference between the treatment groups concerning
sperm count and sperm motility. However, none of the studies
reported the number of motile sperm inseminated.
None of the studies included stated the type of insemination
catheter used.
Two studies (Filicori 2003; Gerli 1993) mentioned cancellation
criteria. The first study stated that on day 21 when no dominant
follicles were seen on ultrasound the cycle was cancelled. The sec-
ond study reported that patients at risk for OHSS based on ultra-
sound findings were cancelled.
Type of outcomes
None of the studies included comparing FSHwith hMG reported
live birth rates but instead all studies reported pregnancy rates per
couple. Ongoing pregnancy rates were not stated. Both studies
of Filicori (Filicori 2001; Filicori 2003) reported the number of
multiple pregnancies andmiscarriages. All studies reported that no
ovarian hyperstimulation syndrome (OHSS) was observed. None
of the studies reported ectopic pregnancies.
B. r-FSH versus u-FSH
Type of participants
All except one study (Gerli 2004 II) included couples with unex-
plained subfertility, male subfertility and ovulatory dysfunction.
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One study (Gerli 2004) included women with endometriosis also,
and one study (Pares 2002) included women with endometriosis
and women with a cervical factor as well. The remaining study
(Gerli 2004 II) included women suffering from PCOS only.
The reported diagnostic investigation and inclusion criteria varied
among these studies. Both studies of Gerli (Gerli 2004; Gerli 2004
II) performed a diagnostic screening including gynaecological and
ultrasound examination, semen analysis, hormonal assessment and
hysterosalpingogram. Matorras 2000 included couples satisfying
the following criteria: a history of infertility > two years, women
age between 18 to 40 years and at least one normal patent tube.
Pares 2002 used the following inclusion criteria: infertility of more
than one year; at least a normal Fallopian tube and a sperm test
better than 1.5 x 10(6)/ml and motility grade 3.
The age of women was stated in all four trials. The mean age in
the r-FSH group was 31.8 ± 3.2 years compared to 31.9 ± 3.3
years in the u-FSH group. All trials reported the mean duration
of subfertility per treatment group: 3.5 ± 1.7 years for the r-FSH
group and 3.8 ± 2.2 years for the u-FSH group.
One of the studies (Gerli 2004 II) mentioned that all women had
received ovulation induction with clomiphene citrate previously.
And one study (Pares 2002) stated that
80% of the women included, suffered from primary subfertility
and they were equally divided between the two treatment groups.
Type of interventions
Two studies (Gerli 2004;Gerli 2004 II) used a protocol comparing
50 IU r-FSH daily with 75 IU u-FSH daily. The other two in-
cluded studies (Matorras 2000; Pares 2002) used 150 IU in both
treatment arms.
All four studies used hCG to trigger ovulation and to time insem-
ination. Both studies of Gerli (Gerli 2004; Gerli 2004 II reported
the use of 10.000 IU hCG.Matorras 2000 used 5000 IU hCGand
the fourth study (Pares 2002) did not mention the hCG dosage.
Gerli 2004) performed a single insemination 32 to 40 hours af-
ter hCG in both studies. Matorras 2000 also performed a single
insemination but after 36 hours. Pares and co-workers insemi-
nated twice in one cycle; 20 and 40 hours after hCG. The semen
preparation technique was stated in two studies only (Matorras
2000; Pares 2002) reporting Pure sperm and Percoll gradient re-
spectively. None of the studies mentioned explicitly that partner
semen was used, although this was most likely. It is noteworthy
that one study (Pares 2002) reported an important difference in
the number of motile sperm injected between treatment groups
(Significant higher in the r-FSH group).
None of the studies included comparing r-FSHwith u-FSH stated
the type of insemination catheter used.
Three studies reported cycle cancellation criteria; cycles were
stopped when > five follicles were 16 mm or more (Gerli 2004
(II)), > six follicles were 15 mm or more and E2 > 1000 pg/ml
(Matorras 2000) and finally, > four follicles 18 mm or more and
E2 >2000 pg/ml or > six follicles >10 to 16 mm (Pares 2002).
Type of outcomes
None of the studies reported live birth rates. One study (Pares
2002) stated ongoingpregnancy rates and all studies reported preg-
nancy rates per couple. Multiple pregnancies and miscarriage rate
were reported by all studies. Finally, Pares 2002 reported the in-
cidence of ovarian hyperstimulation syndrome (OHSS). None of
the studies reported ectopic pregnancies.
C. hMG versus u-FSH versus r-FSH (follitropin alpha) versus r-FSH
(follitropin beta)
Type of participants
Demirol and co-workers included 322 couples with minimal and
mild endometriosis, male factor and unexplained subfertility . Di-
agnostic screening included semen analysis, hysterosalpingogra-
phy or laparoscopy. Couples were included with a history of pri-
mary subfertility of > two years, between 20 to 40 years, normo-
ovulatory status and patent tubes. Male factor subfertility was de-
fined as subnormal sperm analysis according the WHO criteria.
The age of women and duration of subfertility was not stated.
Type of interventions
Ovarian stimulation was started on cycle day 3 with 75 IU go-
nadotrophins if the bodymass index (BMI)was less than 25 kg/m2
and 150 IU if the BMI was > 25 kg/m2. 10.000 IU hCGwas used
to trigger ovulation and time insemination. A single insemination
was performed 36 hours after hCG injection. Semen preparation
was performed with pure sperm. It was not been stated whether
partner semen was used, although this was most likely. The type
of insemination catheter has not been stated. Cycle cancellation
criteria were not stated.
Type of outcomes
This study (Demirol 2002) did not mention live birth rates. Clin-
ical pregnancy rates per cycle were mentioned only.
D. hMG versus u-FSH versus r-FSH (follitropin alpha)
Type of participants
Gurgan and co-workers included 241couples with unexplained
subfertility. Couples with a history of primary subfertility of more
than two years, aged between 20 to 40 years, normal semen analy-
sis, normo-ovulatory status and normal hysterosalpingography or
laparoscopy. The age and duration of subfertility of the included
couples was not stated.
Type of interventions
Ovarian stimulation was started on cycle day 3 with 75 IU of go-
nadotrophins if the BMI was less than 25 kg/m2 and 150 IU if the
BMI was > 25 kg/m2. To trigger ovulation and time insemination,
and injection of 10,000 IU hCGwas given. A single insemination
per cycle was performed 36 hours after hCG injection. Semen
preparation technique was not stated. The type of catheter used
was not stated. Cycle cancellation criteria were decreasing estradiol
levels or more than four follicles of 16 mm of more.
Type of outcomes
Live birth rates were not stated. Clinical pregnancies were stated
only.
6. Gonadotrophins alone versus gonadotrophins combined with
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a GnRH agonist
Five studies (Carrera 2002(I); Carrera 2002(II); Dodson 1991;
Pattuelli 1996; Sengoku 1994) compared gonadotrophins alone
with gonadotrophins combined with a GnRH agonist. One trial
(Pattuelli 1996) was published as an abstract only. One study (
Dodson 1991) reported data per cycle only. In total data of 391
women could be pooled.
Four studies (Carrera 2002 (I); Dodson 1991; Pattuelli 1996;
Sengoku 1994) included couples suffering from unexplained sub-
fertility. Apart from this indication Dodson and co-workers in-
cluded also the indications:male factor, endometriosis and adnexal
adhesions. Carrera 2002 (I) included also male factor subfertil-
ity besides unexplained subfertility. The second study of Carrera
(Carrera 2002 (II)) included women with PCOS only.
The reported diagnostic investigations differed among the tri-
als. Four studies (Carrera 2002(I); Carrera 2002(II); Dodson
1991; Sengoku 1994) reported a complete investigative work-up
consisting of most of the following tests: semen-analysis (except
Carrera 2002 (II)), basal body temperature chart (only stated by
Sengoku 1994), hormone essays, post-coital testing (only reported
by Sengoku 1994), hysterosalpingography, endometrial biopsy
(only reported by Sengoku 1994) and diagnostic laparoscopy (not
reported by Carrera 2002 (I) and only done when abnormalities
were found in the second study of Carrera and co-workers). The
remaining trial was published as an abstract and stated only that
a fertility work-up was performed.
The age of the women was stated in four trials (Carrera 2002(I);
Carrera 2002(II); Dodson 1991; Sengoku 1994). One study
(Dodson 1991) reported the age of women and duration of sub-
fertility for the total group of women included. The mean age in
the gonadotrophins alone group was 30.8 ± 2.3 years compared
to 31.2 ± 2.4 years in the gonadotrophin/GnRH agonist group.
The same trials reported the mean duration of subfertility: 4.0 ±
2.1 years for the gonadotrophins alone group and 4.1 ± 2.0 years
for the gonadotrophin/GnRH agonist group.
One study (Carrera 2002 (II)) reported that women were previ-
ously treated with three cycles with clomiphene citrate. As stated
before, this might introduce selection bias.
Both studies of Carrera and co-workers reported the percentage
of primary infertility which was 100%.
Type of interventions
Different dosages of drugs and different schedules were used in
all trials. The first study of Carrera (Carrera 2002 (I)) stimulated
with 100 IU r-FSH per day from cycle day 3 onwards in both
groups. Procrin was used as GnRH agonist; 1 mg per day from
cycle day 21 of the preceding cycle and 0.5 mg from cycle day 3
of the stimulation cycle. In the second study of Carrera (Carrera
2002 (II)) women were stimulated with 75 IU r-FSH in both
treatment groups. Decapeptyl was used as GnRH agonist 0.1 mg
per day from the preceding cycle day 21 onwards and 0.05 mg
from cycle day 3. The third study (Dodson 1991) stimulated with
75 IU hMG from cycle day 7 in the gonadotrophins only group
and in the gonadotrophin/GnRH agonist group leuprolide 1 mg/
day was applied in the luteal phase 4 to 7 days before the onset
of menstrual period combined with 75 to 225 IU hMG from
cycle day 2 onwards. Pattuelli and co-workers applied 150 IU FSH
in both treatment groups and LHRH from the mid luteal phase
of the preceding cycle in the group where a GnRH agonist was
applied. Finally, Sengoku and co-workers stimulated with 150 IU
hMG per day in both groups. In the treatment group where a
GnRH agonist was applied this was done from cycle day 1; 0.3
mg buserelin acetate three times a day.
All five studies used hCG for timing a single insemination. All
but one study (Sengoku 1994) timed insemination 36 to 40 hours
after hCG injection. Sengoku and co-workers inseminated after
24 to 28 hours. The semen preparation technique was stated in
all studies. Two studies (Carrera 2002 (I) and Carrera 2002 (II))
used the Percoll gradient technique. Two studies (Dodson 1991
and Sengoku 1994) stated a double wash technique and Pattuelli
and co-workers used the swim-up technique. None of the studies
mentioned explicitly that partner semen was used, although this
was most likely. One study (Sengoku 1994) stated the number
of inseminated motile sperm. In both studies of Carrera and co-
workers a Gynetics catheter was used for insemination. One study
(Sengoku 1994) used the Tomcat catheter. The remaining studies
(Dodson 1991 and Pattuelli 1996) did not state the type of in-
semination catheter.
Both studies of Carrera (Carrera 2002 and Carrera 2002 (II))
reported the same cycle cancellation criteria: > three follicles of 18
mm or more or E2 > 1000 pg/ml.
Dodson and co-workers used different cancellation criteria: > seven
follicles of 17mmormore or E2 > 2000 pg/ml. The remaining two
studies (Pattuelli 1996; Sengoku 1994) did not state cancellation
criteria.
Type of outcomes
None of the studies reported live birth rates and all but one study
(Dodson 1991) stated pregnancy rates per couple. Multiple preg-
nancies were reported by three studies (Carrera 2002 I; Carrera
2002 II; Pattuelli 1996). Both studies of Carrera reported miscar-
riage rates and OHSS rates. None of the studies reported ectopic
pregnancies.
7. Gonadotrophins alone versus gonadotrophins combined with
a GnRH antagonist
Five studies (Gomez 2005;Lambalk 2006;Ragni 2001;lScheiber
2003;;Williams 2004) compared gonadotrophins alone with go-
nadotrophins combined with a GnRH antagonist. One study
(Scheiber 2003) was published as abstract only. Two studies
(Scheiber 2003; Williams 2004) reported pregnancy rates per cy-
cle only. In total data of 324 women could be pooled.
The studies (Gomez 2005; Lambalk 2006; Ragni 2001) of which
the results could be pooled included couples with unexplained and
mild male factor subfertility. Scheiber and co-workers included
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women with PCOS and Williams and co-workers included cou-
ples with unexplained subfertility only.
The diagnostic fertility investigations were comparable for the
three studies (Gomez 2005; Lambalk 2006; Ragni 2001). All three
performed cycle analysis, hormone analysis, weight measurement
of women and hysterosalpingography or laparoscopy or both. Se-
men analysis was done twice in the study ofGomez and co-workers
and once in the study of Lambalk and co-workers. Ragni did not
report a semen analysis. The other two studies included (Scheiber
2003 ; Williams 2004) did not state any fertility investigations.
The age of women was stated in four trials (Gomez 2005; Lambalk
2006; Ragni 2001; Williams 2004). The mean age in the go-
nadotrophins alone group was 32.6 ± 3.6 years compared to 33.4
± 3.2 years in the gonadotrophin/GnRH antagonist group. The
mean duration of subfertility was stated in two studies (Lambalk
2006; Williams 2004) which was 2.5 ± 1.7 years for the GnRH
antagonist group and 2.4 ± 1.8 years for the FSH alone group.
Whether previous fertility treatment was advocated was not re-
ported in any of the studies. However, two studies used previous
treatment as selection criteria; no IUI or IVF previously (Williams
2004) and not more than two previous IUI attempts (Lambalk
2006).
One study (Gomez 2005) reported the percentage of primary sub-
fertility which was more than 90% in both treatment groups.
Type of interventions
Different treatment schedules and dosages of drugs were used in
the various trials included. Gomez and co-workers started with
100 IU FSH on cycle day 3 to 4 and when the recruited follicles
were 16 mm or larger or E2 levels were > 300 pg/ml, 0.25 mg
Ganirelix was subcutaneously injected daily until hCG was given.
Lambalk and co-workers started fromday 2 to 3 of menstrual cycle
with r-FSH of which the dose was determined by the investigator
based on patient’s characteristics and history. Ganirelix or placebo
was given (double-blind design) when one or more follicles > 14
mmwere seen, until hCGwas given. Ragni and co-workers started
with a fixed dose of 150 IU r-FSH from day 3 of the cycle until
hCG administration. Cetrorelix was started from the day when
a follicle > 14 mm in mean diameter was visualized until hCG
injection. Scheiber and co-workers started with 150 IU r-FSH
on cycle day 2 to 3 and Ganirelix 0.25 mg was given when the
dominant follicle was 14 mm, E2 > 600 pg/ml or LH > 7.5 IU/l.
Williams and co-workers started with 150 IU r-FSH on day 2 to
3. On day 6 Ganirelix 0.25 mg was initiated and was continued
until administration of hCG.
All five studies used hCG for timing of a single insemination.
However, Ragni and co-workers timed an insemination with LH
urinary test in the control group. All but one study (Ragni 2001)
reported the time interval between hCG injection and insemina-
tion. This time interval varied slightly between the studies, but
all inseminations were planned 32-42 hours after hCG injection.
The semen preparation technique was stated in one study (Gomez
2005) that used a swim-up technique. None of the studies men-
tioned explicitly that partners semen was used, although this was
most likely. One study (Williams 2004) reported the number of
sperm inseminated in each group which was comparable. Both
Gomez (2005) and Scheiber (2003) stated a slight difference of
injected motile sperm between both treatment arms. Only Gomez
and co-workers reported the type of insemination catheter (a Lee
catheter)
Cancellation criteria werementioned in two studies (Gomez 2005;
Ragni 2001). Gomez and co-workers stated that cycles were can-
celled when more than 4 follicles had a diameter of more than 16
mm. Ragni and co-workers stated that cycles were cancelled when
more than 6 follicles had a diameter of 14 mm or more or less
than 2 follicles had a size of 14 mm. The remaining three studies
did not report any cancellation criteria.
Type of outcomes
One of the studies (Gomez 2005) reported live birth rates whereas
three studies (Gomez 2005; Lambalk 2006; Ragni 2001) stated
pregnancy rates per couple and multiple pregnancies. None of the
studies reported miscarriage rates, OHSS rates or ectopic preg-
nancies.
8. Gonadotrophins alone versus gonadotrophins combined with
anti-oestrogens
One study (Ransom 1996) compared gonadotrophins alone with
gonadotrophins combined with anti-oestrogens. This publication
was a full-text paper. Data of 98 women were available.
All coupleswhowere to undergoOHwith IUIwere enrolled in this
study. Indications were: unexplained and male factor subfertility,
endometriosis, cervical factor, ovulatory dysfunction, PCOS and
women with surgically corrected pelvic adhesions.
All participants had to have had a preliminary infertility investiga-
tion, including hysterosalpingogram, postcoital test, semen anal-
ysis and hormonal analysis.
The mean age of the women was 32.9±4.8 years in the group
stimulated with gonadotrophins only and 32.3±3.4 years in the
group where anti-oestrogens were added. Duration of subfertility
was not stated. Previous fertility treatment consisted of at least
three unsuccessful cycles with anti-oestrogens. Previous treatment
with gonadotrophins was reason for exclusion.
Whether couples suffered from primary subfertility was not re-
ported.
Type of interventions
Ransom and co-workers compared a daily dose of 150 IU hMG
from cycle day 3 onwards with 100 mg CC from cycle day 3 to 7
combined with 150 IU hMG on cycle day 7, 9 and 11. When no
mature-sized follicles were present by day 12, hMGwas continued
until a follicle of 18 mm or more was detected.
5000 IUhCGwere used to induce ovulation and 34-36 hours later
one insemination was performed. A standard swim up technique
was used for semen preparation. It was not stated explicitly that
partner semen was used, although this was most likely, since ther-
apeutic donor insemination candidates were excluded. The num-
ber of injected motile sperm was stated and was not significant
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different between both groups (37.2 versus 42.4 x 106). The type
of insemination catheter was not reported. An additional hCG
injection was applied for luteal support.
Cancellation criteria were not stated.
Type of outcomes
Pregnancy rates per groupwere stated aswell asmultiple pregnancy
rates, miscarriage rates and ectopic pregnancies. Ransom and co-
workers did not report OHSS rates.
9. Different dosage regimen for anti-oestrogens or aromatase
inhibitors
One study (Al-Fadhli 2005) compared different dosage regimens
for aromatase inhibitors. This trial was published as an abstract
only.
Couples with unexplained or mild endometriosis were included.
However, diagnostic fertility investigations were not reported in
detail.
The age of women and duration of subfertility were not reported.
Neither previous fertility treatment nor the percentage of primary
subfertility were stated.
Type of interventions
Al-Fadhli 2005 and co-workers compared different dosage regi-
men of aromatase inhibitors; 2.5 mg letrozole for five days versus 5
mg letrozole for five days. Ovulation was triggered with 10.000 IU
hCG and one insemination was performed 24 hours later. The se-
men preparation technique and the type of insemination catheter
were not stated. It was not stated explicitly that partners semen
was used, although this was most likely. The number of injected
spermatozoa was not reported and cancellation criteria were not
stated.
Type of outcomes
Primary outcome was the number of follicles, endometrial thick-
ness and pregnancy rate per cycle. Also the number of multiple
pregnancies were stated. Live birth rates, pregnancy rates per cou-
ple, miscarriage rates, ectopic pregnancies and OHSS were not
reported.
10. Different dosage regimens for gonadotrophins
Four studies (Dhaliwal 2002; Hughes 1998; Ragni 2004; Sengoku
1999) were included comparing different dosage regimens for go-
nadotrophins.
All four articles were full-text papers. In total data of 297 women
could be pooled.
Two studies (Dhaliwal 2002; Sengoku 1999) included couples
with unexplained and ovulatory dysfunction with CC failure.
Hughes and co-workers included women with endometriosis and
tubal disease as well. Ragni 2004 included couples with unex-
plained subfertility, male factor subfertility, endometriosis and
PCOS.
The infertility work-up differed between the four studies. All stud-
ies performed cycle analysis, hormone analysis, semen analysis and
hysterosalpingography or laparoscopy or both. Cervical mucus
testing was done in two studies (Dhaliwal 2002; Sengoku 1999).
Additionally, one study (Sengoku 1999) performed an endome-
trial biopsy and a basal body temperature curve. Ragni 2004) used
a body mass index between 19 to 30 to include women.
The age of women was stated in all four trials. Two trials (Dhaliwal
2002; Sengoku 1999) compared low dose gonadotrophins (75 IU/
day) with high dose gonadotrophin (150 IU/day) and the mean
ages of the women were 30.2±3.9 years and 31.5±4.0 years re-
spectively. One study (Hughes 1998) had three treatment groups.
Ragni and co-workers (Ragni 2004) reported a mean age of
33.1±3.0 years in the high dose group and 32.1±6.6 in the low
dose group.
The mean duration of subfertility was stated in all 4 studies. Du-
ration of subfertility was comparable between studies. However,
Dhaliwal 2002 reported a mean duration of 6.1±2.8 years in the
low dose group versus 6.9±2.9 years in the high dose group in
contrast to the other three studies (Hughes 1998; Ragni 2004;
Sengoku 1999) that reported a mean duration of subfertility of
3.9±2.2 years, 3.1±1.2 years and 4.4±2.3 years respectively.
Previous fertility treatment was reported in all studies but dif-
fered. Dhaliwal and co-workers reported five to six cycles CC use,
Hughes and co-workers reported that 90% of the included women
had CC with IUI before, Ragni (2004) reported previous fertility
treatment was performed but no IUI and finally, Sengoku (1999)
reported previous CC treatment. Three studies (Dhaliwal 2002;
Hughes 1998; Sengoku 1999) reported the percentage of primary
subfertility which was 76%, 67% and 70% respectively.
Type of interventions
Dhaliwal 2002 started with 100 mg CC on cycle day 3 for five
days in both groups combined with 75 to 150 IU hMGdaily from
cycle day 5 in the conventional protocol and 150 IU hMG once
on cycle day 9 in the minimal stimulation protocol. Hughes 1998
compared three different stimulation protocols: Women in group
A applied 150 IU r-FSH on cycle day 4 and 75 IU r-FSH on
cycle day 6 and 8; women in group B applied 150 IU r-FSH on
cycle day 4, 6 and 8 and women in group C applied 150 IU on
cycle day 4, 6, 8 and 10. Ragni (2004) compared two stimulation
protocols: 50 IU r-FSH per day combined with a 0.25 mg GnRH
antagonist from the day in which a follicle > 13 mm in mean
diameter was visualized compared to 50 IU r-FSH on alternate
days combined with the same GnRH antagonist. Finally, Sengoku
(1999) compared 150 IU u-FSH daily, both from cycle day 3
onwards.
All four studies used hCG for timing of a single insemination.
However, timing after hCG differed among the studies; two stud-
ies (Hughes 1998 and Sengoku 1999) timed the insemination 24
to 28 hours after hCG injection and two studies (Dhaliwal 2002;
Ragni 2004) timed insemination 34 to 40 hours after hCG in-
jection. Furthermore, Sengoku and co-workers adjusted timing of
insemination when an LH rise was detected.
The semen preparation technique was stated in two studies:
Dhaliwal 2002 used a swim-up technique, and Sengoku 1999 used
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a double washing technique. None of the studies mentioned ex-
plicitly that partner semenwas used, although this was most likely.
None of the studies stated the number of injected motile sperm.
Two studies (Dhaliwal 2002; Sengoku 1999) reported the type of
insemination catheter (IUI cannula and Tomcat catheter).
Cancellation criteria were reported in two studies (Hughes 1998;
Ragni 2004). The first study stated that cycles were cancelled if no
follicles developed on cycle day 18 or when more than 2 follicles
reached a size of 17 mm or more. The second study stated that
cycles were cancelled when more than 2 follicles > 14 mm. The
remaining studies (Dhaliwal 2002 ; Sengoku 1999) did not state
any cancellation criteria.
Type of outcomes
One of the studies (Ragni 2004) reported live birth rates. All stud-
ies stated pregnancy rates per couple. All but one study (Hughes
1998) stated multiple pregnancy rate per pregnancy, miscarriage
rates and OHSS rates. None of the studies reported ectopic preg-
nancies as an outcome of interest.
11. Other comparisons
The remaining five studies compared different stimulation pro-
tocols, which were not stated beforehand in our protocol; A. oe-
strogens added to anti-oestrogens (Gerli 2000), B. Aromatase in-
hibitor versus gonadotrophins (Jamal 2005), C. GnRHa in dif-
ferent dosages (Kim 1996), D. phyto-oestrogens added to anti-
oestrogens (Unfer 2004) and E. tamoxifen with gonadotrophins
versus anti-oestrogens (Wang 2004). Each has been stated below
separately. Two studies (Jamal 2005; Wang 2004) were published
as abstracts only.
A. Oestrogens added to anti-oestrogens
Type of participants
Gerli (2000) included patients with a subfertility of at least two
years with an oligomenorrhoea or amenorrhoea associated with a
positive menstrual response to an progesterone challenge. Diag-
nostic investigations were not mentioned explicitly, but women
whose partners had abnormal semen analysis (according to the
WHO), women with uterine or tubal abnormalities and women
with a BMI > 25 kg/m2 were excluded.
The mean age of participants was 28±5.6 years for them who re-
ceived clomiphene citrate (CC) plus ethinyl E2 and 26±4.2 years
for patients who received CC alone. The mean duration of sub-
fertility was 48±18.5 months for the CC plus ethinyl E2-group
and 36.7±9.6 months for the CC alone group. In all cases, no
ovulation induction had been tried before.
Type of intervention
From cycle day 3, 100 mg clomiphene citrate (CC) was given for
five days. On cycle day 8, 0.05 mg of ethinyl E2 or placebo was
given for five days.
10,000 IU hCGwas used for timing and 24 to 36 hours after hCG
injection a single intrauterine insemination was performed. The
semen preparation technique and the number of injected motile
sperm were not stated. The type of insemination catheter was not
stated either.
Cancellation criteria were not mentioned. Luteal phase support
with 50 mg progesterone daily was given starting three days after
IUI.
Type of outcomes
Ongoing pregnancy rates were reported defined as gestations that
reached 20 weeks. Miscarriage rate was reported. No other out-
come measures of interest were stated.
B. Aromatase inhibitors versus gonadotrophins
Type of participants
Jamal (2005) included women with unexplained subfertility of at
least two years duration. Diagnostic investigations were not stated.
Inclusion criteria were women between 20 to35 years with FSH
< 10 mIU/ml on cycle day 3. Mean age of participants and the
mean duration of subfertility were not reported.Whether previous
fertility treatment had been performed was stated.
Type of intervention
5 mg aromatase inhibitor (letrozole) daily was administered from
cycle day three for five days. This was compared with 75 IU hMG
daily starting on cycle day 3 for women below 30 years and 150
IU hMG for women > 30 years.
10000 IU hCG was used to trigger ovulation and IUI was per-
formed 34 to 36 hours later.
Type of outcomes
Clinical pregnancy rates were reported.
C. GnRHa in different dosages
Type of participants
Kim (1996) included subfertile women with various stages of en-
dometriosis diagnosed and staged by laparoscopy. Mean age of
participants in the ultra long group was 32.9±2.2 and in the long
protocol group 32.4±2.0 years respectively. Duration of subfertil-
ity was 3.9±1.3 years and 3.2±1.0 years for the ultra long protocol
and long protocol respectively. A part of patients had experienced
previous attempts of medical treatment, but none had received
any medication for at least 6 months.
Type of intervention
The ultra long protocol consisted of one dose of LHRH agonist
(3.75 mg Decapeptyl) administered mid luteal. Four weeks after
the single injection daily administration of 0.1 mg LHRH agonist
was started and continued for at least two weeks prior to ovarian
stimulation. After complete suppression of ovarian function was
confirmedby serumoestradiolmeasurement andpelvic ultrasound
scan 150 mg hMG and 150 mg u-FSH were started. u-FSH was
given for four days only.
The long protocol consisted of daily administration of 0.1 mg
LHRH agonist from the mid luteal phase of the menstrual cycle
preceding the stimulation cycle. After two weeks administration
complete suppression was checked and started with 150 mg hMG
and 150 mg u-FSH. u-FSH was given for four days only.
10.000 IU hCG was given to induce ovulation when one or more
follicles of 18 mm or more were identified. A single IUI was per-
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formed 36 to 40 hours after hCG injection.
Husband semen was used and Precoll gradient method was used
for semen preparation. A Makler insemination catheter was used.
The motile sperm concentration was 86±20.3 x 106 in the ultra
long protocol and 82.1±24.8 x 106 in the long protocol. Luteal
support was supplied (50 mg progesterone).
Cancellation criteria were not stated, but selective embryonic re-
duction was performed at eight weeks of gestation for triplets or
pregnancies of higher order.
Type of outcomes
Clinical pregnancy rate, miscarriage rate and multiple pregnancy
rate were reported.
D. phyto-oestrogens (PE) added to anti-oestrogens
Type of participants
Unfer (2004) included women with at least two years of subfertil-
ity and oligomenorrhoea or amenorrhoea associated with a posi-
tive menstrual response to progesterone challenge test. Hormone
status was checked and couples with male factor subfertility, uter-
ine or tubal abnormalities or overweight women were excluded.
The mean age was 28 ± 5.6 years in the CC+PE group and 26 ±
4.2 years in theCC alone group. Themean duration of subfertility
was 48.1 ± 18.5 months and 36.7 ± 9.6 months for CC + PE and
CC alone respectively. None of the patients had received fertility
treatment in the past.
Type of intervention
Stimulation started on cycle day 3 with 100 mg clomiphene citrate
(CC) for five days. From cycle day three 1500 mg PE or placebo
was administered for ten days.
10.000 IU hCG was given to induce ovulation when there was at
least one follicle with a minimum diameter of 18 mm. A single
IUI was performed 24 to 36 hours after hCG injection. The type
of sperm preparation, the number of inseminated motile sperm or
the type of insemination catheter usedwas not stated. Cancellation
criteria were not reported.
Type of outcomes
Clinical pregnancy defined by visualization of a gestational sac at
the first planned ultrasound examination obtained at six to seven
weeks of pregnancy or a serum B-hCG level over 1400 mIU.
Ongoing pregnancies were defined as gestations that reached 20
weeks’ gestation. Miscarriage rate was reported as well.
E. tamoxifen with gonadotrophins versus anti-oestrogens
Type of participants
Wang (2004) included subfertile couples who failed to develop
an endometrial thickness of at least 8 mm in a previous super
ovulatory cycle.
The mean age of participants and the duration of subfertility were
not reported.
Type of intervention
Ovarian stimulation was initiated with 100 mg CC daily from
cycle day 3 for 5 days or 40 mg tamoxifen citrate (TMX) daily
from cycle day 3 for 7 days. both in combination with 150 IU of
hMG on alternate days starting on cycle day 4.
10.000 IU hCG was given to trigger ovulation when at least one
follicle was 20 mm or larger. A single IUI was performed 24-36
hours after hCG injection. The type of semen preparation, the
number of inseminated motile sperm or the type of insemina-
tion catheter were not stated. Cancelleation criteria were not re-
ported. Luteal phase support was applied with progesterone 200
mg transvaginally per day.
Type of outcomes
Ongoing pregnancy rate and miscarriage rate were reported.
Risk of bias in included studies
See Table 2
Comparison 1: Anti-oestrogens versus gonadotrophins
All but one study (Ecochard 2000) used a parallel design. Discus-
sion remains regarding the most accurate study design. Pros and
cons of parallel and cross-over methods have been discussed ex-
tensively (Cohlen 1998; Daya 1993; Khan 1996; Olive 1995) and
the Handbook of the Cochrane Collaboration advises to include
studies with a parallel design only and cross-over trials only when
pre cross-over data is available. First data extraction was possible
of the study of Ecochard and co-workers.
Two studies (Dankert 2006; Matorras 2002) used a computer
generated random list. Ecochard 2000 used a random number
table and Nakajima 1999 an open randomisation list. Further-
more, four studies (Balasch 1994; Kamel 1995; Karlstrom 1993;
Karlstrom 1998) reported a random design without further de-
scription. Concealment of allocation was adequate in two stud-
ies (Dankert 2006; Ecochard 2000) using third party and opaque
envelopes and inadequate in the study of Nakajima 1999 where
an open randomisation list was used. In the remaining five studies
concealment of allocation was unclear.
Adequate blinding might prevent bias because patients are often
inclined to consider one treatment option as superior. However,
none of the seven included studies used placebos. Three studies
(Dankert 2006; Ecochard 2000; Matorras 2002) analysed their
data according to the intention to treat principle. In two studies
(Balasch 1994; Nakajima 1999) it has not been stated whether
intention to treat analysis was performed and this could not be
derived from the available information. The remaining studies
(Kamel 1995; Karlstrom 1993; Karlstrom 1998) did not analyse
their data according to the intention to treat principle. Balasch
1994 stated no power calculation was performed. Ecochard 2000
performed a power calculation on the basis of cycle numbers and
therefore erroneous. Dankert 2006 performed a power calculation
based on cycle numbers as well. Both studies did not reach ade-
quate numbers. The remaining four studies did not report any-
thing about power calculations. Six studies (Dankert 2006; Kamel
1995;Karlstrom1993;Karlstrom1998;Matorras 2002;Nakajima
1999) reported the number of drop-outs, which varied from none
in the study of Matorras 2002 to 24% for various reasons in the
study of Dankert 2006 and 30% in the study of Karlstrom 1998.
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Details on drop-outs were not given in the latter study. Cycle can-
cellationwas stated in four studies (Dankert 2006; Ecochard 2000;
Kamel 1995; Matorras 2002) explicitly, which varied from 4.9%
(Ecochard 2000) to 12.1% (Dankert 2006). Reasons for cycle can-
cellation were ovarian hyperstimulation, spontaneous ovulation,
no follicles, low oestrogen levels and personal reasons. None of the
studies reported a source of funding.
Comparison 4: Anti-oestrogens versus aromatase inhibitors
All studies included used a parallel design. Two studies (Al-Fozan
2004; Fatemi 2003) used a computer generated random number
table. The other three studies reported a random design without
further description. The concealment of allocation was unclear in
all five studies. None of the studies used blinding. Two studies
(Fatemi 2003; Ozmen 2005) analysed their data according to the
intention to treat principle, but did not state this explicitly. In
the remaining studies (Al-Fozan 2004; El Helw 2002; Sammour
2001) it has not been stated whether intention to treat analysis
was performed and this could not be derived from the available
information. Finally, none of the studies reported a power calcu-
lation. Sammour 2001 reported that none of the included women
dropped out. The other studies did not state drop-outs. None of
the studies reported information on cycle cancellation. None of
the studies reported a source of funding.
Comparison 5: Gonadotrophins versus gonadotrophins
All studies included used a parallel design. Three studies (Demirol
2002; Gerli 2004; Gerli 2004 II) used a computer generated ran-
domisation table and one study (Matorras 2000) used a computer
generated list. The remaining four studies stated that the stud-
ies were randomised without further description. Concealment of
allocation was adequate in three studies (Gerli 2004; Gerli 2004
(II); Matorras 2000) using a third party. Concealment of alloca-
tion in one study (Demirol 2002) was done with sealed envelopes,
without reporting whether these were numbered and opaque. The
other four studies did not report a concealment of allocation.Three
studies (Gerli 2004; Gerli 2004 (II); Matorras 2000) used a single
blinding; patients were blinded with regard to the type of treat-
ment. Matorras 2000 blinded also the ultrasound staff, oestradiol
analysis and sperm laboratory.
Both studies of Filicori did not statewhether they used an intention
to treat analysis, however the results showed that the numbers
randomised match the numbers analysed.
Gerli and co-workers did not use an intention to treat principle
in the publication of 1993 expressing the results as pregnancy
rate per cycle. In both publications of 2004, Gerli and co-workers
performed an intention to treat analysis of started cycles. However
in both studies (Gerli 2004 I and Gerli 2004 II) respectively 2
cycles and 5 cycles were not analysed because these were never
started. Two studies (Matorras 2000; Pares 2002) performed an
intention to treat analysis for pregnancy rate per couple only and
not for pregnancy rate per cycle. Finally, two studies (Demirol
2002; Gurgan 2004) did not state whether they used an intention
to treat analysis and this could not be derived from the available
data.
None of the studies performed or stated a power calculation. Four
studies (Filicori 2003; Gerli 2004; Matorras 2000; Pares 2002)
reported the number of drop-outs varying from none (Matorras
2000) to 8% (Pares 2002). Cycle cancellation was reported in
all but two studies (Demirol 2002; Gurgan 2004). Cycles were
cancelled mostly due to poor response or hyperstimulation. The
percentage of cycle cancellation varied from 0% (Filicori 2001) to
15% (Matorras 2000). None of the studies reported a source of
funding.
Comparison 6: Gonadotrophins alone versus gonadotrophins
combined with a GnRH agonist
Two studies (Dodson 1991; Sengoku 1994) used a cross-over de-
sign and the remaining three studies (Carrera 2002; Carrera 2002
II; Pattuelli 1996) a parallel design. One study (Carrera 2002)
stated they used anumeric list for randomisation.The other studies
stated the studywas randomisedwithout further description.Con-
cealment of allocation was unclear in all cases. None of the studies
used blinding to prevent bias. Four studies (Carrera 2002; Carrera
2002 II; Dodson 1991; Sengoku 1994) did not state whether they
used an intention to treat analysis, however, the results showed that
the numbers randomised match the numbers analysed. Pattuelli
1996 did not use an intention to treat analysis for analysing their
data. Dodson 1991 reported a power calculation based on cycle
numbers which is erroneous. The remaining studies did not state
a power calculation. None of the studies reported drop-out rates.
All studies reported the number of cycles cancelled. This varied
from no cancelled cycles (Sengoku 1994) to 16% (Pattuelli 1996).
None of the studies stated a source of funding.
Comparison 7: Gonadotrophins alone versus gonadotrophins
combined with a GnRH antagonist
All studies (Gomez 2005; Lambalk 2006; Ragni 2001; Scheiber
2003;Williams 2004) used a parallel design. Four studies (Gomez
2005; Lambalk 2006; Ragni 2001; Williams 2004) used a com-
puter generated list for randomisation. Scheiber 2003 stated the
study was randomised without further description. Concealment
of allocation was reported by Williams 2004; opaque envelopes
were used. The study of Lambalk 2006 had a double-blinded de-
sign by using a placebo in the control group. The remaining stud-
ies did not report blinding.
Lambalk and co-workers performed an intention to treat analysis
for the group defined as all randomised subjects who received at
least one dose of r-FSH. In the remaining studies (Gomez 2005;
Ragni 2001; Scheiber 2003;Williams 2004) it has not been stated
whether intention to treat analysis was performed and this could
not be derived from the available information. A power calcula-
tion was stated in two studies (Lambalk 2006; Williams 2004).
Lambalk and co-workers stated that 100 participants per treat-
ment group were needed to be included to detect a difference
of 12 % in PRs between groups. Williams 2004 stated a power
calculation based on cycle numbers and therefore erroneous. The
study of Lambalk and co-workers stated one drop-out since this
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patient had a spontaneous pregnancy before starting treatment
cycle. Cycle cancellation was reported in all studies varying from
11% (Lambalk 2006; Williams 2004) and 33% (Ragni 2001).
Reasons for drop-outs were: insufficient response, no antagonist
because ultrasound was performed too late, no hCG because too
many follicles were detected, conversion to IVF and spontaneous
ovulation. The study of Lambalk 2006 reported they received re-
imbursement per patient from Organon covering expenses made
for execution of the study. Organon provided the study medica-
tion.
Comparison 8: Gonadotrophins alone versus gonadotrophins
combined with anti-oestrogens
The only study (Ransom 1996) included had a parallel design.
Ransom and co-workers used a random number table without
describing concealment of allocation. No blinding was used. This
study did not state whether they used an intention to treat analysis,
however, the results showed that the numbers randomised match
the numbers analysed. Drop-outs and cycle cancellation were not
reported. Finally, neither power calculation nor a source of funding
was reported.
Comparison 9: Different dosage regimens for anti-oestrogens
or aromatase inhibitors
The only study (Al-Fadhli 2005) included had a parallel design.
This study was randomised without further description. Conceal-
ment of allocation was not reported. The abstract did not state
whether an intention to treat analysiswas performed and this could
not be derived from the available information.It was not stated
whether a power calculation was performed. In addition blinding,
drop-outs and cycle cancellation were not reported. No source of
funding was stated.
Comparison 10: Different dosage regimen for gonadotrophins
All studies (Dhaliwal 2002; Hughes 1998;, Ragni 2004; Sengoku
1999) used a parallel design. And all used a computer gener-
ated random number table or a centralized randomisation scheme.
Concealment of allocation was adequately in two studies (Ragni
2004 and Sengoku 1999) using sealed opaque envelopes. Hughes
and co-workers also used numbered sealed envelopes but did not
describe whether these were opaque. Dhaliwal and co-workers did
not report concealment of allocation. None of the studies stated
a form of blinding. Two studies (Ragni 2004; Sengoku 1999)
did not state explicitly whether an intention to treat analysis was
performed but the results showed that the numbers randomised
match the numbers analysed.Two studies (Dhaliwal 2002;Hughes
1998) did not state whether an intention to treat analysis was per-
formed and this could not be derived from the available data. A
power calculation was done in three studies based on cycle num-
bers and therefore erroneous (Hughes 1998; Ragni 2004; Sengoku
1999). Two studies (Hughes 1998; Ragni 2004) reported drop-
outs. Reasons for drop outs were lack of follicle development and
spontaneous ovulation in the study of Hughes 1998 and hyper-
response, low response or personal reasons were reported in the
study of Ragni 2004. All but one study (Dhaliwal 2002) reported
number of cycles cancelled. The number of cycles cancelled varied
from none (Sengoku 1999) to 17% in the study of Hughes 1998.
None of the studies reported a source of funding.
Comparison 11: Other comparisons
The remaining five studies (Gerli 2000; Jamal 2005; Kim 1996;
Unfer 2004; Wang 2004) used a parallel design. Only Kim 1996
defined the randomisation method using a blocked randomisation
list. The other studies stated that the study was randomized with-
out further description. Concealment of allocation was unclear
in all publications. Four studies (Gerli 2000; Kim 1996; Unfer
2004; Wang 2004) did not state that the analysis was performed
by an intention to treat principle but the results showed that the
numbers randomised match the numbers analysed. Wang and co-
workers only stated this principle for pregnancy rates per cycle. In
the remaining study (Jamal 2005) it has not been stated whether
intention to treat analysis was performed and this could not be
derived from the available information. Power calculations were
not reported in any of the studies. Two studies used a placebo in
a double-blind manner (Gerli 2000; Unfer 2004). None of the
studies reported drop-outs, cycle cancellation or a source of fund-
ing.
Effects of interventions
The results of each comparison are presented separately.
Comparison 1: Anti-oestrogens compared with
gonadotrophins
Live birth rates
Dankert 2006 reported live birth rates per treatment arm revealing
no evidence of benefit of one of the treatments (OR 1.1, 95% CI
0.51 to 2.3). Karlstrom 1993 and Karlstrom 1998 reported live
birth rates for the group as a total and not separately per treatment
modality. Contact has been made with the authors but no reply
has been received until now. The other studies did not collect live
birth data.
Pregnancy rate per couple
The results of seven studies (Balasch 1994; Dankert 2006;
Ecochard 2000; Kamel 1995; Karlstrom 1993; Karlstrom
1998; Matorras 2002) including 556 couples, could be pooled.
The pooled effect revealed a significant difference between go-
nadotrophins and anti-oestrogens; using gonadotrophins im-
proved the pregnancy rates per couple significantly (OR 1.8, 95%
CI 1.2 to 2.7). A random-effects model was used for sensitivity
analysis. Using this random-effects model results were no longer
significantly different (OR 1.8, 95% CI 0.97 to 3.3). This implies
that the results are not very robust. No funnel graph was con-
structed since insufficient studies were included.
Multiple pregnancy rate
Four studies (Balasch 1994; Dankert 2006; Matorras 2002;
Nakajima 1999) reported the number of multiple pregnancies.
However, one study (Nakajima 1999) did not report the number
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of couples in each treatment arm. Therefore, data of three stud-
ies (Balasch 1994; Dankert 2006; Matorras 2002) only could be
pooled, expressing multiple pregnancy rates per couple. Balasch
and co-workers reported zero multiples in each treatment group.
Ameta-analysis does not include these ’zero’ values in the analysis,
but this information is important to show low overall rates. The
analysis revealed a non-significant difference between treatment
groups (OR 0.53, 95% CI 0.15 to 1.9).
Reporting the results per pregnancy all four studies that could be
pooled. With anti-oestrogens five multiples were seen out of 51
pregnancies (MPR per pregnancy: 9.8%); with gonadotrophins
seven multiple pregnancies were seen out of 69 pregnancies (MPR
per pregnancy: 10%) and therefore no significant difference was
found between the two treatment modalities (OR 0.96, 95% CI
0.28 to 3.3).
Miscarriage rate
Four studies (Balasch 1994; Dankert 2006; Matorras 2002;
Nakajima 1999) reportedmiscarriage rates. Three studies (Balasch
1994; Dankert 2006; Matorras 2002) reported the number of
couples per treatment arm. Miscarriage rates per couple showed
a non-significant difference (OR 1.1, CI 95% 0.48 to 2.3). With
anti-oestrogens 14 miscarriages were seen out of 51 pregnancies
(miscarriage rate per pregnancy: 27%); with gonadotrophins 15
miscarriages were seen out of 69 pregnancies (miscarriage rate per
pregnancy: 22%). Regarding miscarriage rate per pregnancy, no
significant differencewas foundbetween the two treatmentmodal-
ities (OR 0.73, 95% CI 0.32 to 1.7).
OHSS rate per couple
When pooling the reported outcomes of Balasch 1994 and
Matorras 2002, it showed that there is no significant difference in
OHSS rate between gonadotrophins and clomiphene citrate (OR
4.4, 95% CI 0.48 to 41). Data of 200 couples were included.
Ectopic pregnancy rate was not reported in the included publica-
tions.
Comparison 2: Anti-oestrogens compared with
gonadotrophins with GnRH agonists
This comparison was not the subject of any randomised controlled
trial.
Comparison 3: Anti-oestrogens compared with
gonadotrophins with GnRH antagonists
This comparison was not the subject of any randomised controlled
trial.
Comparison 4: Anti-oestrogens compared with aromatase in-
hibitors
Live birth rates
None of the included studies reported live birth rates.
Pregnancy rates per couple
The five trials (Al-Fozan 2004; El Helw 2002; Fatemi 2003;
Ozmen 2005; Sammour 2001) included 313 couples in total.
There is no evidence of benefit in using letrozole compared to
clomiphene citrate (OR 1.2, 95% CI 0.64 to 2.1). No funnel
graph was constructed since insufficient studies were included.
Multiple pregnancy rates
One study (Al-Fozan 2004) reported multiple pregnancy rates. A
total of 154 couples were included and one multiple pregnancy
occurred in the CC group and none in the letrozole group. The
result per couple was not statistically significant different (OR
0.36, CI 95% 0.01 to 8.9).
Miscarriage rate
One study (Al-Fozan 2004) reported miscarriage rates per preg-
nancy including 154 couples. In the group treated with aromatase
inhibitors no miscarriages were reported; in the anti-oestrogen
group four miscarriages were seen. The results per couple showed
a non-significant difference (OR 0.26, 95% CI 0.01 to 7.0). The
same result was seen for miscarriage rate per pregnancy (OR 0.06,
95% CI 0.001 to 1.3).
OHSS rate per couple
None of the included studies reported the incidence of OHSS per
group.
Ectopic pregnancy rate was not reported by any of the included
studies.
Comparison 5: Gonadotrophins alone compared with go-
nadotrophins alone.
In total nine trials compared different types of gonadotrophins.
None of these reported live birth rates per couple.
hMG versus FSH
Pregnancy rate per couple
Three studies (Filicori 2001; Filicori 2003; Gerli 1993) compared
hMG with FSH including 132 couples. There is no evidence of
benefit in using hMG compared to FSH (OR 2.2, 95% CI 0.91
to 5.1). No funnel graph was constructed since insufficient studies
were included.
Multiple pregnancy rates
Two studies (Filicori 2001; Filicori 2003) comparing 150 IU FSH
daily with 150 IU hMG daily reported multiple pregnancy rates
per treatment group. Data of 100 couples were available. Four
multiple pregnancies were reported in the hMG-group with 50
couples and five in the r-FSH group with also 50 couples result-
ing in a non significant difference (OR 1.27, 95% CI 0.32 to
5.0). With 150 IU FSH daily five multiples were seen out of nine
pregnancies (MPR per pregnancy: 56%); with 150 IU hMG daily
four multiple pregnancies were seen out of 13 pregnancies (MPR
per pregnancy: 30%). This result was not statistically significant
different (OR 2.88, 95% CI 0.49 to 16.8).
Miscarriage rates
Both studies of Filicori and co-workers reported miscarriage rates
per couple and per pregnancy. In both groups of 50 couples each
two miscarriages were reported, resulting in a non-significant dif-
ference (OR 1.0, 95% CI 0.14 to 7.4). In the FSH group twomis-
carriages were reported out of nine pregnancies (miscarriage rate
per pregnancy: 22%) with hMG two miscarriages were seen out
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of 13 pregnancies (miscarriage rate per pregnancy: 15%). There is
no statistically significant difference in miscarriage rate per preg-
nancy between these two gonadotrophins (OR 0.64, 95%CI 0.07
to 5.6).
OHSS rates per couple
None of the studies comparing hMG with FSH reported OHSS
rates.
Ectopic pregnancy rate per couple
None of the studies comparing hMG with FSH reported ectopic
pregnancies.
u-FSH versus r-FSH
Pregnancy rate per couple
Four studies (Gerli 2004; Gerli 2004 (II); Matorras 2000; Pares
2002) compared u-FSH with r-FSH, including 444 couples. No
significant difference in PRs per couple was found between ovarian
stimulation with r-FSH and ovarian stimulation with u-FSH (OR
1.2, 95% CI 0.81 to 1.8). No funnel graph was constructed since
insufficient studies were included.
Multiple pregnancy rates
A total of 223 couples were included in the r-FSH group and 221
in the u-FSH group. There was a non-significant difference in
multiple pregnancy rate per couple (OR 0.86, 95% CI 0.37 to
2.0). With r-FSH 11 multiples were seen out of 86 pregnancies
(MPR per pregnancy: 13%); with u-FSH 13 pregnancies were
seen out of 78 pregnancies (MPR per pregnancy: 17%).
Miscarriage rates
All four studies included reported miscarriage rates. There was a
non-significant difference in miscarriage rate per couple between
r-FSH and u-FSH (OR 1.4, 95% CI 0.64 to 3.0). In the r-FSH
group 16 miscarriages out of 80 pregnancies were seen (miscar-
riage rate per pregnancy: 20%). In the u-FSH group 12 miscar-
riages were reported out of 75 pregnancies (miscarriage rate per
pregnancy: 16%).
OHSS rate per couple
Pares 2002 reported one case of OHSS in the group treated with
r-FSH compared with no cases of OHSS in the group treated with
u-FSH which was not significantly different (OR 0.36, 95% CI
0.01 to 9.1). This study included 116 couples.
Ectopic pregnancy rate per couple
None of the studies comparing u-FSH with r-FSH reported ec-
topic pregnancy rates.
Comparison 6: Gonadotrophins alone compared with go-
nadotrophins with GnRH agonists.
Live birth rate per couple
None of the studies included reported live birth rates.
Pregnancy rate per couple
Five studies performing this comparison (Carrera 2002; Carrera
2002 (II); Dodson 1991; Pattuelli 1996; Sengoku 1994). Four
trials revealed data on pregnancy rates per couple including 415
couples. The pregnancy rate was significant different between both
treatment groups favouring gonadotrophins alone (OR 1.8, 95%
CI 1.1 to 3.0). No funnel graph was constructed since insufficient
studies were included. Sengoku 1994 used a cross-over design
reporting pregnancy rates per couple after the first cycle. Dodson
1991 used a cross-over design as well without stating live births or
pregnancy rates before cross-over and was therefore excluded.
Multiple pregnancy rates
Three studies (Carrera 2002; Carrera 2002 (II); Pattuelli 1996)
reported multiple pregnancy rates per treatment group. Data were
available for 324 couples. Multiple pregnancy rate per couple re-
vealed a non-significant difference between the treatment groups
(OR 2.7, 95% CI 0.96 to 7.4). With gonadotrophins alone five
multiple pregnancies were seen out of 37 pregnancies (MPR per
pregnancy: 14%); gonadotrophins combined with a GnRH ag-
onist resulted in 13 multiple pregnancies out of 33 pregnancies
(MPR per pregnancy: 39%). This revealed a statistically signifi-
cant higher multiple pregnancy rate per pregnancy when a GnRH
agonist had been added (OR 4.5, 95% CI 1.4 to 15).
Miscarriage rates
Both studies of Carrera and co-workers reported miscarriage rates
for each treated group. Data were available of 300 couples. The
miscarriage rate per couple was comparable between both treat-
ment arms (OR 1.0, 95% CI 0.2 to 5.1). With gonadotrophins
alone three miscarriages were seen out of 10 pregnancies (mis-
carriage rate per pregnancy: 30%). In the group gonadotrophins
combined with GnRH agonists, there were three miscarriages out
of 17 pregnancies (miscarriage rate per pregnancy: 18 %). This
result was not statistically significant (OR 0.51, 95% CI 0.08 to
3.13).
OHSS rate per couple
Two studies (Carrera 2002; Carrera 2002 (II) ) reported OHSS
rates. When using gonadotrophins alone six OHSS were seen out
of 60 women compared with 11 OHSS out of 60 women using
gonadotrophins combined with a GnRH agonist. This result was
not statistically significant (OR 2.0, 95% CI 0.69 to 5.9).
Ectopic pregnancy rate per couple
None of the studies included reported rates of ectopic pregnancies.
Comparison 7: Gonadotrophins alone compared with go-
nadotrophins with GnRH antagonists.
Live birth rates
One study (Gomez 2005), including 80 couples, reported live
birth rates. This result showed a statistically significant difference
in live birth rates when a GnRH antagonist is added (OR 3.0,
95% CI 1.1 to 8.6). However, the results are based on one study
with small numbers, which implies that this result is not robust.
Pregnancy rates per couple
Five IUI studies (Gomez 2005; Lambalk 2006; Ragni 2001;
Scheiber 2003; Williams 2004) compared gonadotrophins alone
with gonadotrophins combined with a GnRH antagonist. Data
of 299 couples were available. The results of three studies could
be pooled. The pooled effect showed that there is no evidence of
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benefit in the addition of a GnRH antagonist compared to go-
nadotrophins alone (OR 1.5, 95% CI 0.83 to 2.8). No funnel
graph was constructed since insufficient studies were included.
The remaining two studies (Scheiber 2003;Williams 2004) stated
pregnancy rates per cycle only. Scheiber and co-workers found that
r-FSH with an antagonist is superior to r-FSH alone in prevent-
ing cycle cancellation for premature luteinization without show-
ing a significant improvement in pregnancy rates. Williams and
co-workers found that the clinical pregnancy rate per cycle initi-
ated was higher in the GnRH antagonist group without reaching
statistical significance.
Multiple pregnancy rates
Three studies (Gomez 2005; Lambalk 2006; Ragni 2001) reported
multiple pregnancy rates per treatment group.Data of 424 couples
were available. There was a non-significant difference in multi-
ple pregnancy rates per couple between both treatment arms (OR
0.67, 95% CI 0.19 to 2.5). With gonadotrophins alone five mul-
tiple pregnancies were seen out of 22 pregnancies (MPR per preg-
nancy: 23%); with gonadotrophins combined with a GnRH an-
tagonist three multiple pregnancies were seen out of 31 pregnan-
cies (MPR per pregnancy: 9.6%), resulting in a non-significant
difference (OR 0.48 95% CI 0.12 to 1.94).
Miscarriage rates
None of the studies comparing gonadotrophins with go-
nadotrophins combined with GnRH antagonists reported miscar-
riage rates as secondary outcome.
OHSS rate per couple
None of the studies included reported OHSS rates per treatment
group.
Ectopic pregnancy rate per couple
None of the studies included reported ectopic pregnancy rates.
Comparison 8: Gonadotrophins in combination with anti-oe-
strogens versus gonadotrophins alone.
Live birth rate
The study of Ransom 1996 did not report live birth rates per
treatment group.
Pregnancy rate per couple
Ransom 1996 included 98 couples and the results showed a sta-
tistically significant difference in favour of hMG alone (OR 3.1,
95% CI 1.3 to 7.6). However, only one study has been included
with a small number of participants, therefore this result is not
very robust.
Other secondary outcomes (multiple pregnancies, miscarriages,
OHSS or ectopic pregnancies) were not stated.
Comparison 9: Different dosage regimens for anti-oestrogens
or aromatase inhibitors.
One small trial (Al-Fadhli 2005) including 98 couples, compared
two different doses of letrozole (aromatase inhibitor). Pregnancy
rates per cycle were stated only, showing that 5.0 mg letrozole sig-
nificantly improved pregnancy rates (29.6% versus 6.3%). Mul-
tiple pregnancy rate was zero in both groups. Other secondary
outcomes were not reported.
Comparsion 10: Different dosage regimens for
gonadotrophins.
Live birth rates
Live births were reported in one study (Ragni 2004) including 63
couples, comparing daily dose of gonadotrophins 50 IU with al-
ternate day dose of gonadotrophins (50 IU), both combined with
aGnRHantagonist. The overall live birth rate per recruited couple
was 30% in patients treated daily and 3% for patients treated on
alternate days, respectively. The results showed a statistically signif-
icant difference in favour of daily treatment with gonadotrophins
combined with a GnRH antagonist (OR 14, 95% CI 1.6 to 116).
However, these results are probably not robust since a small num-
ber of participants were included.
Pregnancy rate per couple
Four studies were included comparing different dosage regimens
for gonadotrophins (Dhaliwal 2002; Hughes 1998; Ragni 2004;
Sengoku 1999). However, the stimulation protocols were com-
pletely different among these studies. Two studies (Dhaliwal
2002; Sengoku 1999) including 297 couples compared 75 IU go-
nadotrophins daily with 150 IU gonadotrophins daily. The pooled
effect revealed that there is no evidence of benefit using 150 IU
gonadotrophins per day compared to 75 IU per day (OR 1.2, 95%
CI 0.69 to 1.9).
The third study (Hughes 1998) included 63 women in total and
compared three ovarian stimulation regimens; Group A: 150 IU r-
FSH on day 4 and 75 IU r-FSH on day 6 and 8; Group B: 150 IU
r-FSH day 4, 6 and 8; Group C: 150 IU r-FSH day 4, 6, 8 and 10.
Cycle completion was the primary objective of this analysis, but
pregnancy rates were also stated. Two pregnancies occurred during
study cycles, both in Group B, with no statistically significant
difference among groups (5.4% versus 0% and 0%).
The fourth study (Ragni 2004) compared 50 IU r-FSHdaily com-
bined with a GnRH antagonist with 50 IU r-FSH on alternate
days combined with a GnRH antagonist. A preliminary evalua-
tion of results revealed a strong difference between the two groups
in terms of pregnancy rate. A statistically significant higher preg-
nancy rate per couple was observed in the group of patients treated
with daily r-FSH (37% versus 6%) (OR 9.0, 95% CI 1.8 to 45).
Multiple pregnancy rate
Two studies (Dhaliwal 2002; Sengoku 1999) compared low dose
regimens of gonadotrophins versus high dose regimens. Data of
297 couples were available. There was a non-significant difference
in multiple pregnancy rate per couple between both treatment
arms (OR3.1, 95%CI0.48 to 20).With lowdose gonadotrophins
one multiple pregnancy was seen out of 42 pregnancies (MPR per
pregnancy: 2.4%); with a high dose gonadotrophins four multiple
pregnancies were seen out of 46 pregnancies (MPR per pregnancy:
8.7%). However meta-analysis did not show a statistically signifi-
cant difference per pregnancy (OR 3.4, 95% CI 0.46 to 25).
Ragni 2004 reported zero multiples in both treatment groups.
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Miscarriage rate
Two studies (Dhaliwal 2002; Sengoku 1999) comparing low dose
with high dose regimens reported miscarriage rates. Data of 297
couples were used. There was a non-significant difference in mis-
carriage rate per couple between both treatment arms (OR 0.28,
95% CI 0.08 to 1.1). Ten miscarriages were seen in the group
treated with high dose gonadotrophins (miscarriage rate per preg-
nancy: 22%). In the group treatedwith lower dose gonadotrophins
three miscarriages were seen out of 42 pregnancies (miscarriage
rate: 7%). Using a low dose regimen of gonadotrophins resulted in
a non-significant lower miscarriage rate per pregnancy (OR 0.28,
95% CI 0.07 to 1.1).
OHSS rate per couple
Whenahigh dose of gonadotrophinswas given, theOHSS ratewas
significantly higher than using a low dose of gonadotrophins (OR
5.52, 95% CI 1.85 to 16.52) (Dhaliwal 2002; Sengoku 1999).
The random-effects model showed comparable significance (OR
5, 95% CI 1.6 versus 15). However, both models show a wide
confidence interval and a relative small number of included par-
ticipants which implies that results are not very robust. With a
low dose gonadotrophins four OHSS were seen out of 149 cycles
(OHSS rate per cycle: 2.7%); with a high dose gonadotrophins 19
OHSS were seen out of 148 cycles (OHSS rate per cycle: 13%).
Data of 297 couples was used. Clinically, these results are of rele-
vance.
Ectopic pregnancy rate per couple
None of the studies included reported the incidence of ectopic
pregnancies.
Other comparisons
A. Oestrogens added to anti-oestrogens
Gerli 2000 included 64 women and the number of ongoing preg-
nancies was 12/32 in the CC+ ethinyl E2 group and 2/32 in the
CC alone group. The results showed a statistically significant im-
provement of clinical pregnancy rates when ethinyl E2was applied
(OR 9.0, 95% CI 1.8 to 44). However, since the power of the
study is limited this result is not robust. The miscarriage rate was
statistically significant higher in the CC alone group (6/32 versus
2/32).
B. Aromatase inhibitor versus gonadotrophins
Jamal 2005 included 80 women and the number of clinical preg-
nancies was not statistically significant different between both
groups (7/40 in the letrozole group versus 6/40 in the hMGgroup).
C. GnRHa in different dosages
Kim 1996 included 80 patients and there was a statistically signifi-
cant higher clinical pregnancy rate per couple in the ultra long pro-
tocol group (19/39 versus 11/41) (OR 2.6, 95% CI 1.02 to 6.6).
Miscarriage rate was similar in both groups (4/19 ultra long pro-
tocol and 2/11 long protocol), multiple pregnancies were higher
in the ultra long protocol group (3/19 in the ultra long protocol
group versus 1/11in the long protocol).
D. phyto-oestrogens added to anti-oestrogens
Unfer 2004 included 134 patients and reported ongoing preg-
nancy rates of 13/65 in the CC+PE group versus 3/69 in the CC
alone group. The addition of phytoestrogens improved pregnancy
rates significantly (OR 5.5, 95%CI 1.5 to 20). However it is most
likely that power of the study is too small to draw firm conclusions
as illustrated by the wide confidence interval. Miscarriage rates
were statistically significant higher in the CC alone group (6/9 in
the CC alone group versus 2/15 in the CC+PE group).
E. tamoxifen with gonadotrophins versus anti-oestrogens
Wang 2004 included 48 women and reported an ongoing preg-
nancy rate of 4/32 in the CC group and 6/16 in the tamoxifen
group. This result was not statistically significantly different. Mis-
carriage rate was similar between treatment groups (5/9 in the CC
group and 1/7 in the tamoxifen group).
D I S C U S S I O N
Intra-uterine insemination combined with OH has been proven
effective for couples with unexplained and mild male factor sub-
fertility (Cohlen 2000;Verhulst 2006). Compared with IVF, IUI
with OH is less invasive and more cost-effective (Goverde 2000).
There remains discussion regarding the optimal stimulation drug
and protocol not only taken into account the probability of con-
ception but also unwanted side-effects (multiples, OHSS) and
costs.
The aim of this review was to evaluate different ovarian stimu-
lation protocols for intrauterine insemination for all indications
with regard to live birth rates, pregnancy rates, multiples, miscar-
riages and OHSS rate. Data could be pooled for six of the eleven
comparisons stated in themethod section of this review. Of course
there are a number of methodological considerations to be taken
into account when interpreting the results. We will discuss each
comparisons in detail.
Comparison 1: Anti-oestrogens compared with
gonadotrophins
The results demonstrated that in an IUI program ovarian stim-
ulation with gonadotrophins increases pregnancy rates per cou-
ple significantly, compared to anti-oestrogens, without effecting
adverse outcomes. However, these results are not very robust and
clinical differences should be taken into account.
One of the differences between the studies included is that
Matorras 2002 used donor sperm for insemination treating severe
male factor subfertility (41% azoospermia), single women or cou-
ples where protected intercourse was necessary due to a HIV pos-
itive status of one of the partners. Thus, one might conclude that
they did not treat subfertile women but healthy women not yet
subjected to the chance of achieving conception. AlthoughMator-
ras and co-workers compared FSH with CC, which was the com-
parison of interest, we performed a sensitivity analysis excluding
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this trial. The pooled effect of this latter analysis showed higher
pregnancy rates using gonadotrophins compared to clomiphene
citrate but this effect was no longer statistically significant (OR
1.4 95% CI 0.86 to 2.3).
Another meta-analysis, performed by Hughes 1997, concluded
that gonadotrophins seem to be more effective compared with
CC. This statement was based on twenty-two trials of which three
investigated this comparison directly. Costello 2004 also reviewed
studies comparing CC with gonadotrophins both combined with
IUI.They included three studies in theirmeta-analysis that showed
a significant higher pregnancy rate per cycle when treated with
gonadotrophins. All three studies included in their review were
included in this present review, but in addition we included four
more trials.
Other confounding clinical factors that might influence the re-
sults of this comparison might be the dosage of anti-oestrogens
or gonadotrophins used. All studies used comparable dosages of
gonadotrophins (75 to150 IU) and anti-oestrogens (50 to100 mg)
but different regimens. Balasch 1994 started with gonadotrophins
75 IU on cycle day 7 only, whereas other studies started on cycle
day 3.
Another striking clinical difference was that Ecochard 2000 stim-
ulated with 150 IU gonadotrophins on day 4, 6, 8 and 9 of the
cycle instead of daily injections such as in the other six trials.
Stimulation on alternating days was also done in an other study
(Hughes 1998) with disappointing results, which might indicate
that a daily dosage of ovarian stimulation is necessary instead of
this form of ’coasting’.
Apart from this, Ecochard 2000 was the only trialist to use a differ-
ent method for timing insemination depending on the detection
of spontaneous LH surges. They inseminated 36 hours after hCG
or 24 hours after a detected LH surge, while the other studies in-
seminated between 35 and 42 hours after hCG injection only. Un-
fortunately, the study results did not report whether spontaneous
LH surges were seen significantly more in one of two treatment
groups. Extracting this study from the meta-analysis shows a sta-
tistically significant difference in favour of gonadotrophins (OR
2.00 95% CI 1.29 to 3.10).
The methodological quality of the six trials included was similar:
all but one (Ecochard 2000) used a parallel design and three trials
mentioned an adequate method of randomisation (Dankert 2006;
Ecochard 2000;Matorras 2002).
Although it is generally believed that gonadotrophins results in sig-
nificant higher multiple pregnancy rates compared to clomiphene
citrate, we could not conclude this with the available data.
Comparison 4: Anti-oestrogens compared with aromatase in-
hibitors
None of the trials solely or in combination provided convinc-
ing evidence of a significant difference. It has been suggested that
clomiphene citrate would result in higher miscarriage rates com-
pared to letrozole as reported by one of the smaller studies included
(Al-Fozan 2004). More evidence is needed to confirm this obser-
vation. Since costs are important it is important to realize that
letrozole costs ten times more than clomiphene citrate (Kompas
2001). This aspect should be considered when there is no evidence
of benefit. All trials used a parallel design and two studies men-
tioned adequate methods of randomization.
Comparison 5: Gonadotrophins alone compared with go-
nadotrophins alone for example FSH versus HMG
There is no convincing evidence of a difference comparing r-FSH
with u-FSH combining both treatments with IUI. However, there
are confounding factors that might influence this conclusion.
Among these factors are: 1. Different daily dosages of go-
nadotrophins were used and compared. Both studies of Gerli 2004
compared a higher dose of urinary FSH (75 IU) with a lower dose
of recombinant FSH (50 IU), which might result in lower preg-
nancy rates with recombinant FSH than expected when the same
dose would have been used. However, in view of the apparent in-
creased bioactivity of recombinant FSH over urinary FSH prod-
ucts one might consider this a correct comparison (Out 1995).
The other studies in the meta-analysis compared similar dosages
of r-FSH and u-FSH (Matorras 2000; Pares 2002) that showed
a non-significant trend in favour of r-FSH (OR 1.4 95% CI
0.83 to 2.5). The same has been concluded for patients suffering
from clomiphene citrate resistant chronic anovulation (Coelingh
Bennink1998), but it has also been refuted by others (Yarali 1999).
2. Timing of insemination. All studies inseminated once between
32 to 40 hours after hCG injection; only Pares 2002 inseminated
twice (20 and 40 hours after hCG). A previous Cochrane review
did not detect an additional value of a second insemination (
Cantineau 2003).
Nowadays costs should be included into decision making, whereas
u-FSH is 33 to 50 % cheaper (Kompas 2001;Gerli 2004). On the
other hand, according to previous literature recombinant prod-
ucts have certain advantages such as higher batch-to-batch con-
sistency, high purity, avoiding injection of potentially allergenic
proteins, the likelihood of reducing the risk of infectious particles,
rendering the production independent of urine collection and the
elimination of drugs co-extracted from urine. (Matorras 2000;No
authors listed 98). All trials were methodological comparable and
used a parallel design and adequate randomisation methods.
This review has also shown there is no evidence to suggest which is
better FSH or hMG. There was no significant difference between
21Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the treatments, but the trials were too small to draw firm conclu-
sions.
When the studies were compared in detail, clinical heterogeneity
was observed; Gerli 1993 used a higher dose of gonadotrophins
(225 IU) in both treatment groups compared to the other studies
(150 IU).Moreover, a LHRH agonist was given during the luteal
phase, which is different from the other studies. When the studies
of Filicori were pooled (Filicori 2001; Filicori 2003) neither of the
two types of gonadotrophins was significantly better (OR 1.60,
95% CI 0.61 to 4.17).
There was a significant reduction in the total amount of go-
nadotropins used in favour of hMG, which should be taken into
account regarding treatment costs. The same was concluded for
in vitro fertilisation and intracytoplasmic sperm injection cycles
recently (Al-Inany 2005). All trials used a parallel design and none
of the trials mentioned the method of randomisation.
Comparison 6: Gonadotrophins alone compared with go-
nadotrophins with GnRH agonists
There is evidence that adding a GnRH agonist to gonadotrophins
does not improve pregnancy rates, while increasing the probability
of achieving a multiple pregnancy.
Comparing the studies in detail did not provide large differences in
potential clinical confounding factors. Only Sengoku 1994 used a
different timing of insemination; 24 to 28 hours after hCG, which
did not show completely bad results in pregnancy rates although
previous literature (Andersen 1995) stated that the time interval
between hCG injection to follicular rupture is approximately 38
hours, which might be the perfect moment for insemination. One
study (Sengoku 1994) had a cross-over design, but the first data
only were used. Only one study mentioned their method of ran-
domisation (Carrera 2002). In conclusion, adding GnRH agonists
to gonadotrophins does not improve treatment outcome. Bearing
these data in mind, together with the fact that GnRH agonists
are expensive, their use should be carefully considered in an in-
trauterine insemination program. This conclusion is in line with
a previous publication ( Dodson 1991 II).
Comparison 7: Gonadotrophins alone compared with go-
nadotrophins with GnRH antagonists
Adding a GnRH antagonist showed promising results. Analysing
the largest study (Lambalk 2006) in detail that included 100 cou-
ples in each treatment arm, reported the use of a placebo which
filtered out possible bias. However, the amount of gonadotrophins
applied in this trial was unclear because the starting dosage de-
pended on the choice of the investigator treating the patient.
Another study in this analysis (Gomez 2005), which showed a sig-
nificant difference favouring treatment with a GnRH antagonist,
started to apply the antagonist only when the dominant follicle
reached a size of 16 mm or when the oestradiol levels were higher
than 300 pg/ml.While the other trials startedwith aGnRH antag-
onist when dominant follicles reached a size of 14 mm. Moreover,
there was a significant difference found in the number of domi-
nant follicles at the moment of hCG injection between treatment
groups in this study of Gomez and co-workers (higher number of
dominant follicles in the group treated with GnRH antagonists).
A placebo was not used and therefore clinicians were not blinded
in this study. This might have lead the clinicians to stimulate
ovaries more aggressively when an antagonist was added, resulting
in significantly more dominant follicles in the antagonist group,
and thus more pregnancies. This should be taken into account
when the results of themeta-analysis are interpreted. It is clear that
future well-randomised trials, consisting of at least 300 couples,
should lead to a definite answer whether GnRH antagonist are
cost-effective and efficient.
Comparison 10: Different dosage regimens for
gonadotrophins (High dose (more than75 IU per day) versus
low dose gonadotrophins (75 IU or less per day))
Based on small numbers our results show that doubling the daily
dose of gonadotrophins per day from 75 IU to 150 IU does not
result in improvement of treatment outcome.
There may be a minimum acquired dose of gonadotrophins be-
cause both Hughes and Ragni reported extremely low pregnancy
rates when a very low-dose regimen is given on alternating days.
This might also be an effect of the alternating day regimen, al-
though the half-life for r-FSH is around 30 to 40 hours (Mannaerts
1996).
Considering cost-effectiveness, this is an important finding. Espe-
cially when multiple pregnancies are taken into account as well.
Multiple pregnancy rates have been discussed extensively in liter-
ature (Fauser 2005; Nan 1994). Using high dose gonadotrophins
seems to lead to more multiple pregnancies without improving
pregnancy rates significantly, which is an interesting outcome of
this review.Of course, these results are based on relative small num-
bers with a wide confidence interval. However, there is increasing
evidence from national registries, that mild ovarian hyperstimu-
lation combined with national guidelines of cancellation criteria
reduces the risks of multiples (< 10 % twins and 1% triplets) with
acceptable pregnancy rates per cycle and couple (;Haagen 2006;
Steures 2006).
Finally, the results imply, based on available data of 297 couples,
that OHSS rate is significantly higher when a high dose stimu-
lation protocol is used. It seems logical to assume that the more
aggressive an ovarian stimulation protocol is, the higher OHSS
rates will be.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We advise the authors of the NICE guidelines to take into account
the up-to-date evidence presented in this review.
1. Based on the available results gonadotrophins might be the
most effective drugs when IUI is combined with ovarian hyper-
stimulation. However, this result is not very robust and more re-
search is needed. Anti-oestrogens appear to be cost effective in IUI
programs, although they seem somewhat less effective compared
to gonadotrophins. Users should be aware of the fact that anti-
oestrogens do not prevent multiples and that an anti-oestrogenic
effect on the endometrium has been reported.
2. When gonadotrophins are applied we advise to apply it on a
daily basis. Low dose protocols (50 to 75 IU per day) are advised
since pregnancy rates do not seem to differ significantly from preg-
nancy rates with high dose regimens (> 75 IU per day) whereas the
changes to encounter negative effects from ovarian stimulation,
such as the risk of multiples and the risk of OHSSmight be higher
with high dose protocols.
3. There seems to be no role for GnRH-agonists in IUI programs
as they increase costs tremendously and increase the number of
multiples without increasing the probability of conception. We
therefore advise not to use GnRH agonists in this setting, if mild
ovarian hyperstimulation is applied.
4. Whether or not urinary gonadotrophins should be used as first
choice compared with recombinant products is more a discussion
of purity, trace ability and costs. There is no convincing evidence
of a significant difference in the probability of conception.
5. Whether or not GnRH-antagonists are going to play a role in
mild ovarian hyperstimulation/IUI programs needs to be deter-
mined in future trials.
6. From the available data there is no convincing evidence that
letrozole is superior to clomiphene citrate and therefore the cost
should be taken into account when using anti-oestrogens.
Implications for research
In general, it is important to provide data about the efficacy of
ovarian stimulation combined with IUI for all women suffering
from subfertility. However, clear definition of the study popula-
tion is also needed to assess the effectiveness of treatment in daily
practice. Using placebos in a control group will improve the qual-
ity of studies.
Suggested randomised controlled trials that need to be done:
To compare clomiphene citrate with gonadotrophins combined
with IUI in a prospective designed randomised study for unex-
plained subfertility (including power calculation)
To compare clomiphene citrate with gonadotrophins combined
with IUI in a prospective designed randomised study formildmale
factor subfertility (including power calculation)
To compare gonadotrophins with gonadotrophins combined with
a GnRH antagonist in a prospective randomised study including
cost-efficacy for unexplained and mild male subfertility.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Al-Fadhli 2005























Interventions stimulation method/ dosage:
letrozole 2,5 mg daily for 5 days
letrozole 5,0 mg daily for 5 days
trigger for ovulation: hCG
(10 000 IU)
timing IUI;
24 hrs after hCG
frequency of IUI:
once
semen prep technique: not stated
no of sperm injected: not stated
type of semen:
nl SA, thus husband semen
catheter used:
not stated
cancellation criteria: not stated
Outcomes PR/cycle
multiples
number of ampoules used: not applicable
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Al-Fadhli 2005 (Continued)
number of dominant follicle (>17 mm):
2.5 mg letrozole: 1.1±0.0
5 mg letrozole: 1.3±0.1
Notes comparison 9
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Al-Fozan 2004

























Interventions stimulation method/ dosage:
letrozole 7,5 mg daily for 5 days
CC 100 mg daily for 5 days
trigger for ovulation: hCG
(10000 IU)
timing IUI;
24 and 48 hrs after hCG
frequency of IUI:
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Al-Fozan 2004 (Continued)
twice
semen prep technique: not stated
no of sperm injected: not stated
type of semen:
not stated explicitly but normal SA
catheter used:
not stated
cancellation criteria: not stated
Outcomes ongoing PR/ women
PR/cycle
ectopic pregnancy
miscarriage rate per pregnancy
multiple PRs
number of ampoules used: not applicable




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Balasch 1994
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Interventions stimulation method/ dosage:
FSH 75 IU daily from CD 7
CC 50 mg daily for 5 days
trigger for ovulation: hCG
(10.000)
timing IUI;
35-36 hrs after hCG
frequency of IUI:
once
semen prep technique: swim up into medium






cancellation criteria: not stated
Outcomes ongoing PR/ women
PR/cycle
miscarriage rate per pregnancy
multiple PRs
OHSS
number of ampoules used:
not stated
number of dominant follicle:
not stated
Notes comparison 1
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Carrera 2002


























Interventions stimulation method/ dosage:
Group A: rFSH 100 IU/d from CD3
Group B: GnRHagonist 1 mg/d from CD 21 + rFSH 100 IU/d from CD 3 and 0.5 mg/d
GnRHa from CD 3 (Procrin)
trigger for ovulation: hCG
(10000)
timing IUI;
36-38 hrs after hCG
frequency of IUI: once
semen prep technique: Percoll gradient
no of motile sperm injected: A: 9.6±4.3 x10 6





cancellation criteria: >3 foll > 18 mm E2 > 1000 pg/ml
Outcomes ongoing PR/ women
PR/cycle
miscarriage rate per pregnancy
multiple PRs
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Carrera 2002 (Continued)
OHSS
number of ampoules used:
Group A: 11.3 Group B: 16.5




number of dominant follicles significant higher in group B
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Carrera 2002 (II)






















3 cycles with CC
primary subfertility;
not stated
Interventions stimulation method/ dosage:
Group A: rFSH 75 IU/d from CD3
Group B: GnRHagonist 0.1 mg/d from CD 21 + rFSH 75 IU/d from CD 3 + GnRHa 0.
05 mg
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Carrera 2002 (II) (Continued)
(Decapeptyl)
trigger for ovulation: hCG
(10000)
timing IUI;
36-38 hrs after hCG
frequency of IUI: once
semen prep technique: Percoll gradient
no of motile sperm injected:
A: 11.9±4.3 x106
B: 12.7±4.1
type of semen: not stated
catheter used:
Gynetics catheter
cancellation criteria: >3 foll > 18 mm E2 > 1000 pg/ml
Outcomes ongoing PR/ women
PR/cycle
miscarriage rate per pregnancy
multiple PRs
OHSS
number of ampoules used:
Group A: 17.6 Group B: 20.8
number of




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Dankert 2006







12 FSH group patients (24%)
cycle cancellation:
CC group: 17 cycles
















Interventions stimulation method/ dosage:
CC 100 for 5 days
rFSH 75 IU/d from CD3
trigger for ovulation: hCG
(5000)
timing IUI;
38-40 hrs after hCG
frequency of IUI:
once
semen prep technique: not stated
no of motile sperm injected: not stated
type of semen: husband semen
catheter used:
not stated
cancellation criteria: not stated
Outcomes ongoing PR/ women
PR/cycle
miscarriage rate per pregnancy
multiple PRs
number of ampoules used:
not stated
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Demirol 2002
























Interventions stimulation method/ dosage:
rFSH, uFSH and hMG
BMI < 25 75 IU
BMI> 25 150 IU
from CD 2-3
trigger for ovulation: hCG
timing IUI;
36 hrs after hCG
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semen prep technique: Puresperm
no of motile sperm injected:
not stated
type of semen:
nl SA thus husband semen
catheter used:
not stated
cancellation criteria: not stated
Outcomes PR/cycle











Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Dhaliwal 2002












CC/hMG minimal 28.5± 4.2
CC/hMG convent 30.1±4.6
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CC/hMG convent 6.9±2.9 (yrs)
type of subfertility
unexplained








Interventions stimulation method/ dosage:
CC/hMG convent 100 mg CC daily day 3-7 hMG 75-150 IU daily day 5-9
CC/hMG minimal
CC 100 mg daily day 3-7
hMG 150 IU once day 9
trigger for ovulation: hCG (5000)
timing IUI;
36-40 hrs after hCG
frequency of IUI:
once
semen prep technique: swim-up





cancellation criteria: not stated




miscarriage rate per pregnancy
OHSS
number of ampoules used:
minimal: 2
conventional: 12±5.4




Risk of bias Risk of bias
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Dhaliwal 2002 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Dodson 1991












first cycles not stated
159 cycles













Interventions stimulation method/ dosage:
hMG: 75 IU daily from CD 7
hMG/leuprolide:
4-7 days before onset of menstrual period leuprolide 1 mg/day sc. until hCG injection
hMG: CD 2-3 75-225 IU
trigger for ovulation: hCG
(5000)
timing IUI;
40 hrs after hCG
frequency of IUI: once
semen prep technique: double wash
no of motile sperm injected: not stated
type of semen:
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Dodson 1991 (Continued)
nl SA thus husband semen
catheter used:
not stated
cancellation criteria: >7 foll > 17 mm E2 > 2000 pg/ml
Outcomes live births
ongoing pregnancy
ectopic pregnancy for the total group




number of ampoules used: hMG/leuprolide:
30.3±11.3
hMG: 21.8±6.1




no first data available
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Ecochard 2000
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Interventions Stimulation method/ dosage:
CC: 50-100 mg daily day 3-7
hMG: 150 IU/d day 4,6,8,9
trigger for ovulation: hCG
(5000)
timing IUI;
36 hrs after hCG
or 24 hrs after LH surge + hCG
frequency of IUI:
once
semen prep technique: Percoll density gradient












OHSS for total group
number of ampoules used:
not stated






Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Ecochard 2000 (Continued)
Allocation concealment (selection bias) Low risk A - Adequate
El Helw 2002






















Interventions Stimulation method/ dosage:
Letrozole: 20 mg single dose CD3 CC: 100 mg/d day 3-7
trigger for ovulation: hCG
(5000)
timing IUI;
36 hrs after hCG
frequency of IUI:
once
semen prep technique: not stated
number of motile sperm injected: not stated, but not sign diff
type of semen:
not stated explicitly but normal SA
catheter used:
not stated
cancellation criteria: not stated
Outcomes pregnancy/ couple
number of ampoules used: not applicable
number of dominant follicle
comparable in both groups
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El Helw 2002 (Continued)
Notes comparison 4
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Fatemi 2003























Interventions Stimulation method/ dosage:
Letrozole: 2,5 mg CD3-7
CC: 100 mg/d day 3-7
trigger for ovulation: endogeneousLH surge
timing IUI;
24 hrs after LH surge
frequency of IUI: once
semen prep technique: not stated
no of motile sperm injected: not stated
type of semen:
not stated explicitly but normal SA
catheter used:
not stated
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Fatemi 2003 (Continued)
cancellation criteria: not stated
Outcomes pregnancy/ couple
PR/cycle
number of ampoules used:
not applicable




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Filicori 2001





















ovulation induction in some women
primary subfertility: not stated
Interventions Stimulation method/ dosage:
LHRHagonist single dose in MLP-phase
r-FSH 150 IU/d
hMG: 150 IU/d
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Filicori 2001 (Continued)
trigger for ovulation: hCG
(10000)
timing IUI;
36 hrs after hCG
frequency of IUI: once
semen prep technique: swim up technique
no of motile sperm injected: not stated
type of semen:
not stated explicitly, but seems husband semen
catheter used:
not stated





miscarriage rate per pregnancy
number of ampoules used:
FSH:33.6±2.4
hMG:23.6±1.1




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Filicori 2003











47Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)













ovulation induction in some women (9 in rFSH group and 13 in hMG)
primary subfertility: not stated
Interventions Stimulation method/ dosage:
LHRHagonist single dose in MLP-phase
rFSH: 150 IU/d
hMG: 150 IU/d
trigger for ovulation: hCG
(10000)
timing IUI;
36 hrs after hCG
frequency of IUI:
once
semen prep technique: swim up technique










miscarriage rate per pregnancy
number of ampoules used:
FSH: 25.3±1.3
hMG:21.7±0.8




Risk of bias Risk of bias
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Filicori 2003 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Gerli 1993






















primary subfertility: not stated
Interventions Stimulation method/ dosage:
both groups LHRHagonist single dose in MLP-phase
r-FSH 225 IU/d
hMG: 225 IU/d
trigger for ovulation: hCG
(5000)
timing IUI;
12 and 36 hrs after hCG
frequency of IUI: twice
semen prep technique: swim up technique
no of motile sperm injected: not stated
type of semen: not stated explicitly, but seems husband semen
catheter used:
not stated
cancellation criteria: patients at risk for OHSS based on ultrasound hCG was withheld
49Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)





number of ampoules used:
FSH:40.2±7.5
hMG:35.0±8.0




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Gerli 2000
























Interventions Stimulation method/ dosage:
CC 100 mg for 5 days
50Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
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Gerli 2000 (Continued)
CC/ ethinyl E2: 100 mg CC for 5 days + E E2 0.05 mg day 8-12
CC/placebo: 100 mg day 2-7 and placebo day 8-12
trigger for ovulation: hCG
(10000)
timing IUI;
24-36 hrs after hCG
frequency of IUI:
once
semen prep technique: not stated
no of motile sperm injected: not stated
type of semen:
nl SA thus husband semen
catheter used:
not stated
cancellation criteria: > 5 follicles > 16 mm
Outcomes pregnancy/ couple
PR/cycle
miscarriage rate per pregnancy
number of ampoules used: not applicable
number of dominant follicle
not stated
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Gerli 2004











Participants 67 women138 cycle sage of women:uFSH: 31.7±3.4rFSH: 31.2±3.2duration of subfer-
tility:uFSH: 2.8± 1.3rFSH: 2.9±1.5type of subfertility ovulatory factor male factor unex-
plained fertility treatment;not stated primary subfertility;not stated
51Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
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Gerli 2004 (Continued)




trigger for ovulation: hCG
(10000)
timing IUI;
32-40 hrs after hCG
frequency of IUI: once
semen prep technique: not stated
no of motile sperm injected:
not stated
type of semen:
nl SA thus husband semen
catheter used:
not stated







number of ampoules used: uFSH: 10.9±3.6
rFSH: 11.9± 4.1




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
52Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gerli 2004 (II)
Methods randomisation: random number table
Trial design: parallel
power calculation: not stated
drop-outs: not stated









duration of subfertility: u-FSH: 2.2+1.4
r-FSH: 2.3+1.3
type of subfertility: PCOS women with a history of at least two years of subfertility
previous fertility treatment: ovulation induction with CC




trigger for ovulation: hCG (10.000)
timing IUI: 32-40 hours after hCG
frequency of IUI: once
semen preparation technique: not stated
no of motile sperm injected:
not stated
type of semen: semen analysis thus husband semen is likely.
catheter used: not stated





number of ampoules: u-FSH: 11.3±4.3
r-FSH: 10.8±4.9




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
53Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
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Gerli 2004 (II) (Continued)
Allocation concealment (selection bias) Low risk A - Adequate
Gomez 2005































Interventions Stimulation method/ dosage:
FSH/GnRHanta: 100 IU/d 5 days
GnRHanta from DF 16 mm or when E2 > 300 pg/ml 0.25 mg sc
FSH alone: 100 IU/d from CD3-4
trigger for ovulation: hCG
(5000)
timing IUI;
36-38 hrs after hCG
frequency of IUI:
once
semen prep technique: swim up technique
54Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
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Gomez 2005 (Continued)




nl SA thus husband semen
catheter used:
Lee catheter
cancellation criteria: > 4 follicles > 16-20 mm





miscarriage rate per pregnancy
number of ampoules used:
FSH/GnRHanta: 10±3
FSH alone: 9±3




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Gurgan 2004
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insemination (IUI) in women with subfertility (Review)









Interventions Stimulation method/ dosage:
BMI < 25 75 IU/d CD 2-3
BMI> 25 150 IU/d
CD 2-3
for rFSH, uFSH and hMG
trigger for ovulation: hCG
(10000)
timing IUI;
36 hrs after hCG
frequency of IUI:
once
semen prep technique: not stated
no of motile sperm injected: not stated
type of semen:




cancellation criteria: low E2 levels, > 4 follicles > 15 mm
Outcomes pregnancy/ couple
PR/cycle









Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
56Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)







Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk D - Not used
Hughes 1998
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Hughes 1998 (Continued)
Interventions Stimulation method/ dosage:
A: rFSH day 4 150 IU, day 6 and 8 75 IU/d
B: rFSH day 4, 6 and 8 150 IU/d
C; rFSH day 4,6,8,10 150 IU/d
trigger for ovulation: hCG
(5000)
timing IUI;
24 hrs after hCG
frequency of IUI:
once
semen prep technique: not stated
no of motile sperm injected: not stated
type of semen:
nl SA thus husband semen
catheter used:
not stated
cancellation criteria: no follicle development on day 18. >2 follicles > 17 mm
Outcomes pregnancy/ couple
PR/cycle
number of ampoules used:
A: 4, B: 6, C: 8





Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
58Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
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Jamal 2005






















Interventions stimulation method/ dosage:
letrozole 5 mg/d CD 3-7
hMG 75 IU/d CD 3 for < 30 years
hMG 150 IU/d CD 3 for > 30 years
trigger for ovulation: hCG
(10000)
timing IUI;
34-36 hrs after hCG
frequency of IUI:
once
semen prep technique: not stated





number of dominant follicle
letrozole 1.8±1.3
hMG 3.2± 1.6
cancellation criteria: not stated
Outcomes PR/ women
PR/cycle
number of dominant follicle
letrozole 1.8±1.3
hMG 3.2± 1.6
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Jamal 2005 (Continued)
number of ampoules used:
not stated
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Kamel 1995

























Interventions stimulation method/ dosage:
CC 50 mg/d CD 3-7
hMG 75 IU/d CD 3
trigger for ovulation: hCG
(10000)
timing IUI;
36-42 hrs after hCG
frequency of IUI: once
semen prep technique: not stated
60Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
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Kamel 1995 (Continued)
no of motile sperm injected: not stated
type of semen:
nl SA thus husband semen
catheter used: not stated
cancellation criteria: not stated
Outcomes PR/ women
PR/cycle
number of ampoules used: not stated




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Karlstrom 1993
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Karlstrom 1993 (Continued)
primary subfertility;
not stated for the subgroup IUI
Interventions stimulation method/ dosage:
CC 100 mg/d CD 3-7





36-41 hrs after hCG
frequency of IUI: once
semen prep technique: method of self-migration in hyaluronic acid
no of motile sperm injected:
CC: 10.7 x 106




Kremer de la fontaine or TDT catheter
cancel criteria: not stated
Outcomes PR/ women
PR/cycle
number of ampoules used: not stated
number of dominant follicles: not stated
Notes comparison 1
Not only IUI but also DIPI and DIPI with IUI combined!!
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
62Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
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Karlstrom 1998


























Interventions stimulation method/ dosage:
CC 100 mg/d CD 3-7
hMG: 150 IU/d from CD 2-3
trigger for ovulation: hCG
(10000)
or LH surge in CC group
timing IUI;
38 hrs after hCG
or day after LH peak
Frequency of IUI: once
semen prep technique: not stated





cancellation criteria: not stated
Outcomes PR/ women
PR/cycle
number of ampoules used:
not stated
63Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
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Karlstrom 1998 (Continued)
number of dominant follicle: not stated
Notes comparison 1
extended study from study 1993
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Kim 1996
























endometriosis type I tm IV
previous fertility treatment;




Interventions stimulation method/ dosage:
ultra long:GnRHa3.75mg IM4weeks before starting dailywithGnRHa0.1mg combined
with FSH/hMG
long: GnRHa 0.1 mg 2 weeks daily followed by FSH/hMG
64Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
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Kim 1996 (Continued)
trigger for ovulation: hCG
(10000)
timing IUI;
36-40 hrs after hCG
frequency of IUI:
once
semen prep technique: Percoll gradient
no of motile sperm injected: not stated
type of semen:
nl SA thus husband semen
catheter used:
Makler cannula
cancellation criteria: not stated




miscarriage rate per pregnancy
number of ampoules used:
ultra long: 36.4±8.4
long: 35.3±8.3




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Lambalk 2006
















FSH alone: 32.5±3.9 years
duration of subfertility:







not more than 3 previous IUI attempts
primary subfertility;
not stated
Interventions stimulation method/ dosage:
GnRHanta: rFSH starting dose decided by the investigator + GnRHantagonist when DF
>14mm
FSH alone: rFSH + placebo from DF > 14 mm
trigger for ovulation: hCG (5000 or 10000)
timing IUI;
34-42 hr after hCG injection
frequency of IUI:
once
semen prep technique: not stated





cancellation criteria: not if more than 3 follicles were more or equal 14 mm
Outcomes ongoing PR/ women
PR/cycle
multiple pregnancy rates
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Lambalk 2006 (Continued)
miscarriage rate
number of ampoules used:
GnRHanta: 8
FSH alone: 8
number of dominant follicle
GnRHanta (>18 mm): 1.3±0.6
FSH alone:1.2±1.0
Notes comparison 7
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Matorras 2000
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Matorras 2000 (Continued)
Interventions Stimulation method/ dosage:
rFSH: 150 IU/d
uFSH: 150 IU/d
trigger for ovulation: hCG
(5000)
timing IUI;
36 hrs after hCG
frequency of IUI: once
semen prep technique: Pure sperm
no of motile sperm injected: not stated
type of semen:
husband semen
catheter used: not stated




miscarriage rate per pregnancy
number of ampoules used:
rFSH: 19.2±7.0
uFSH: 23.8±10.8




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
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Matorras 2002


























94% in total group
Interventions Stimulation method/ dosage:
CC: 100 mg/d CD 5-9
uFSH: 150 IU/d
from CD2
trigger for ovulation: hCG
(5000)
timing IUI;
36 hrs after hCG
frequency of IUI:
once
semen prep technique: Pure sperm
no of motile sperm injected: not stated
type of semen:
donor
catheter used: Frydman catheter




miscarriage rate per pregnancy
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Matorras 2002 (Continued)
OHSS
number of ampoules used: not stated




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Nakajima 1999























Interventions Stimulation method/ dosage:
dosages of CC not stated
dosages of rFSH not stated
trigger for ovulation: hCG
(dose ?)
timing IUI;
28-36 hrs after hCG
or after positive ovulation prediction kit
70Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
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semen prep technique: not stated
no of motile sperm injected: not stated
type of semen:
not stated
catheter used: not stated
cancellation criteria: not stated
Outcomes PR/cycle
multiple pregnancy rate
miscarriage rate per pregnancy
number of ampoules used:
not stated




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk C - Inadequate
Ozmen 2005
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Interventions Stimulation method/ dosage:
letrozole: 5 mg/d CD 3-7
CC: 100 mg/d CD 3-7
trigger for ovulation: hCG
(dose unknown)
timing IUI;
33-36 hrs after hCG
frequency of IUI: once
semen prep technique: density gradient
no of motile sperm injected: not stated
type of semen:
not stated explicitly
catheter used: not stated
cancellation criteria: not stated
Outcomes pregnancy/ couple
PR/cycle
number of ampoules used: not applicable




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
72Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
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Pares 2002






























80% of each group
Interventions stimulation method/ dosage:
rFSH 150 IU daily from CD 3
uFSH 150 IU daily from CD 3
trigger for ovulation: hCG
(dose unknown)
timing IUI;
20 and 40 hrs after hCG
frequency of IUI:
twice
semen prep technique: Percoll gradient
no of motile sperm injected: rFSH: 14.3±13.5
uFSH: 11.3±11.4 x106
type of semen:
nl SA thus husband semen
catheter used:
not stated
cancellation criteria: >4 follicles > 18 mm E2 > 2000 pg/ml or > 6 follicles > 10-16 mm
73Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
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Pares 2002 (Continued)
Outcomes ongoing PR/ women
PR/cycle
miscarriage rate per pregnancy
multiple pregnancy rate
OHSS
number of ampoules used:
rFSH: 13.7±4.9
uFSH: 15.2±6.5




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Pattuelli 1996
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Pattuelli 1996 (Continued)
Interventions Stimulation method/ dosage:
LHRH inmid luteal phase FSH 150 IU CD1-5 subsequent dose was adjusted individually
FSH 150 IU/d CD2-6
trigger for ovulation: hCG
(10000)
timing IUI;
38-40 hrs after hCG
frequency of IUI: once
semen prep technique: swim up technique
no of motile sperm injected: not stated
type of semen:
husband semen
catheter used: not stated





number of ampoules used: not stated
number of dominant follicle: not stated
Notes comparison 6
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Ragni 2001








Group A: 7 cycles
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Interventions Stimulation method/ dosage:
Group A: FSH 150 IU/d from CD3; when DF>14 0.25 mg GnRHantagonist









semen prep technique: not stated
no of motile sperm injected: not stated
type of semen:
not stated
catheter used: not stated




number of ampoules used:
Group A: 15±4
Group B: 15±3




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Ragni 2004





Group A: 3 patients withdrew
cycle cancellation:




















Interventions Stimulation method/ dosage:
Group A: FSH 50 IU/d; when DF>14 0.25 mg GnRHantagonist






34 hrs after hCG
frequency of IUI:
once
semen prep technique: not stated
no of motile sperm injected: not stated
type of semen:
nl SA thus husband semen
catheter used: not stated
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Ragni 2004 (Continued)
miscarriage rate per pregnancy
OHSS
number of ampoules used:
not stated




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Ransom 1996


























max 3 cycles of CC
primary subfertility:
not stated
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Ransom 1996 (Continued)
Interventions Stimulation method/ dosage:
Group A: hMG 150 IU/d CD 3





34-36 hrs after hCG
frequency of IUI:
once
semen prep technique: standard swim-up
no of motile sperm injected: rA: 37.2±25.5
B: 42.4±31.7 x106
type of semen:
nl SA thus husband semen
catheter used: not stated




miscarriage rate per pregnancy
number of ampoules used:
not stated




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Sammour 2001

























Interventions stimulation method/dosage: letrozole: 2,5 mg CD 3-7





24 and 48 hrs after hCG
frequency of IUI: twice
semen prep technique: not stated
no of motile sperm injected: not stated
type of semen:
not stated explicitly
catheter used: not stated
cancellation criteria: not stated
Outcomes pregnancy/ couple
number of ampoules used:
not applicable
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Sammour 2001 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Scheiber 2003























Interventions Stimulation method/ dosage:
Group A: rFSH 150 IU/d CD2-3 + GnRHantagonist
from DF> 14 mm





32-40 hrs after hCG
frequency of IUI:
once
semen prep technique: not stated
no of motile sperm injected:
not significant
type of semen:
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Scheiber 2003 (Continued)
nl SA thus husband semen
catheter used: not stated
cancellation criteria: not stated
Outcomes PR/cycle
number of ampoules used:
not stated
number of dominant follicle
not stated
Notes comparison 7
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Sengoku 1994























Group A: 32 (71%)
Group B: 34 (74%)
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Sengoku 1994 (Continued)
Interventions stimulation method/ dosage:
Group A: hMG 150 IU/d CD3
Group B: hMG 150 IU/d CD3 + GnRHa 300 uG 3 dd 1 from CD1
trigger for ovulation: hCG
(10000)
timing IUI;
24 -28 hrs after hCG
frequency of IUI: once
semen prep technique: washed twice by centrifugation
no of motile sperm injected: A: 18.2±8.9
B: 18.8±9.5 x106
type of semen:
nl SA thus husband semen
catheter used:
Tom cat catheter




miscarriage rate per pregnancy
multiple pregnancy rate not from first cycle
OHSS
number of ampoules used:
Group A: 19±8
Group B: 19±6




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
83Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
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Sengoku 1999






















Group I: 33 (69%)
Group II: 35 (71.4%)
Interventions Stimulation method/ dosage:
uFSH: 150 IU/d from CD 3
uFSH: 75 IU/d
from CD 3
trigger for ovulation: hCG
(5000)
timing IUI;
24-28 hrs after hCG When LH surge was detected IUI was the next morning performed
frequency of IUI:
once
semen prep technique: washed twice









miscarriage rate per pregnancy
OHSS
number of ampoules used:
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Sengoku 1999 (Continued)
uFSH (150): 19±7
uFSH (75): 13± 6




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Unfer 2004













Group A: 28± 5.6
Group B: 26± 4.2
duration of subfertility:
Group A: 48.1±18.5







Interventions stimulation method/ dosage:
Group A: CC 100 mg/d CD 3-7 + phytooestrogens 1500 mg/d CD3-12
Group B: CC 100 mg/d CD 3-7 + placebo
trigger for ovulation: hCG
(10000)
timing IUI;
24-36 hrs after hCG
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semen prep technique: not stated
no of motile sperm injected: not stated
type of semen:
nl SA thus husband semen
catheter used:
not stated
cancellation criteria: not stated
Outcomes ongoing PR/ women
miscarriage rate
for the total group
OHSS
number of ampoules used:
not applicable
number of dominant follicle
not stated
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk C - Inadequate
Wang 2004
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Wang 2004 (Continued)
super ovulatory cycles with IUI
primary subfertility;
not stated
Interventions stimulation method/ dosage:
- CC 100 mg daily for 5 days
- TMX 40 mg daily for 5 days + hMG 150 IU on alternate days from CD 4
trigger for ovulation: hCG
(10000)
timing IUI;
24-36 hrs after hCG
frequency of IUI:
once
semen prep technique: not stated





cancellation criteria: not stated
Outcomes PR/ women
PR/cycle
miscarriage rate per pregnancy
multiple pregnancy rate
number of ampoules used:
not applicable




Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Williams 2004






Group A: 4 cycles














not IUI or IVF
primary subfertility;
not stated
Interventions stimulation method/ dosage:
Group A: rFSH 150 IU/d from CD 2-3 + GnRHantagonist
from CD 6
Group B: rFSH 150 IU/d from CD 2-3
trigger for ovulation: hCG (10000)
timing IUI;
34-40 hrs after hCG
frequency of IUI: once
semen prep technique: not stated
no of motile sperm injected:
FSH+anta: 34
FSH: 26 x 106
type of semen:
nl SA thus husband semen
catheter used:
not stated
cancellation criteria: not stated
Outcomes PR/cycle
multiple pregnancy rate stated but not per pregnancy
number of ampoules used:
not stated
number of dominant follicle (>16 mm)
Group A: 1.8
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk D - Not used
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Allegra 1990 retrospective study
also intracervical insemination
Allegra 1990 (II) retrospective study
Alvarez 1999 not randomized
Not only IUI but also directed coitus was performed
Arcaini 1996 superovulation with IUI was compared with superovulation alone which is not the comparison of interest
Brami 2004 comment/ translation of a review
Chang 1993 retrospective study
Check 1992 quasi-randomised study randomised by date of birth
Crosignani 2005 review article
DiMarzo 1992 retrospective study
Doyle 1991 ovarian stimulation with hMG and timed coitus was compared with hMG combined with intrauterine
insemination
Isaza 2000
Isaza 2003 Quasi-randomised study randomised by odds-even
Jacobson 1991 not adequately randomised.
Jaroudi 1998 ovarian stimulation combined with IUI was compared with ovarian stimulation combined with timed
intercourse
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(Continued)
Manganiello 1997 observational study
Matorras 1999 abstract contains same data as included trial with the reference: Matorras 2000
Mitwally 2002 observational cohort study
Mitwally 2003 non-randomised prospective study
Mitwally 2003 (II) not the comparison of interest
literature review
Mitwally 2004 non-randomized study
Mitwally 2005 retrospective study
Nappi 2000 not the comparison of interest
overview
Nava 2004 quasi-randomised study
Nuojua-Huttunen 1997 non- randomised study
Papageorgiou 1995 IUI in natural cycles compared with IUI after mild ovarian stimulation
Prentice 1995 ovarian stimulation combined with IUI compared with expectant management
quasi-randomized by alternating record numbers
Ruddock 2004 not the comparison of interest
case report
Steinkampf 1993 ovarian stimulations compared without IUI
Taskin 2005 clinical trial, not randomized
Tummon 1997 ovarian stimulation combined with IUI compared with no treatment for infertility
Vasiljevic 2000 non randomized study
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D A T A A N D A N A L Y S E S
Comparison 1. anti-estrogens versus gonadotrophins




participants Statistical method Effect size
1 live birth rate per couple 1 138 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.51, 2.26]
2 pregnancy rate per couple 7 556 Odds Ratio (M-H, Fixed, 95% CI) 1.76 [1.16, 2.66]
3 multiple pregnancy rate per
couple
3 338 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.15, 1.86]
4 multiple pregnancy rate per
pregnancy
4 120 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.28, 3.28]
5 miscarriage rate per couple 3 338 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.48, 2.29]
6 miscarriage rate per pregnancy 4 120 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.32, 1.67]
7 OHSS rate per couple 2 200 Odds Ratio (M-H, Fixed, 95% CI) 4.44 [0.48, 41.25]
8 ectopic pregnancy rate per
couple
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. anti-estrogens versus aromatase inhibitors




participants Statistical method Effect size
1 live birth rate per couple 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 pregnancy rate per couple 5 313 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.64, 2.08]
3 multiple pregnancy rate per
couple
1 154 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.01, 8.87]
4 multiple pregnancy rate per
pregnancy
1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.26 [0.01, 7.03]
5 miscarriage rate per couple 1 154 Odds Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 2.16]
6 miscarriage rate per pregnancy 1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.06 [0.00, 1.31]
7 OHSS rate per couple 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 ectopic pregnancy rate per
couple
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 5. different types of gonadotrophins




participants Statistical method Effect size
1 live birth rate per couple 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 A). hMG versus FSH 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 B). r-FSH versus u-FSH 2 4 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 pregnancy rate per couple 9 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 A). hMG versus FSH 5 373 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.59, 1.75]
2.2 B). r-FSH versus u-FSH 5 605 Odds Ratio (M-H, Fixed, 95% CI) 1.36 [0.95, 1.94]
3 multiple pregnancy rate per
couple
6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 A). hMG versus FSH 2 100 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.20, 3.09]
3.2 B). r-FSH versus u-FSH 4 444 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.37, 1.97]
4 multiple pregnancy rate per
pregnancy
6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 A). hMG versus FSH 2 22 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.06, 2.03]
4.2 B). r-FSH versus u-FSH 4 164 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.30, 1.76]
5 miscarriage rate per couple 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 A). hMG versus FSH 2 100 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.14, 7.39]
5.2 B). r-FSH versus u-FSH 4 444 Odds Ratio (M-H, Fixed, 95% CI) 1.40 [0.64, 3.04]
6 miscarriage rate per pregnancy 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 A). hMG versus FSH 2 22 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.07, 5.62]
6.2 B). r-FSH versus u-FSH 4 155 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [0.58, 3.01]
7 OHSS rate per couple 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 A). hMG versus FSH 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 B). r-FSH versus u-FSH 1 116 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.01, 9.11]
8 ectopic pregnancy rate per
couple
0 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 A). hMG versus FSH 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 B). r-FSH versus u-FSH 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. gonadotrophins alone versus gonadotrophins with GnRH agonist




participants Statistical method Effect size
1 live birth rate per couple 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 pregnancy rate per couple 4 415 Odds Ratio (M-H, Fixed, 95% CI) 1.81 [1.10, 2.97]
3 multiple pregnancy rate per
couple
3 324 Odds Ratio (M-H, Fixed, 95% CI) 2.66 [0.96, 7.35]
4 multiple pregnancy rate per
pregnancy
3 70 Odds Ratio (M-H, Fixed, 95% CI) 4.45 [1.36, 14.55]
5 miscarriage rate per couple 2 120 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.19, 5.14]
6 miscarriage rate per pregnancy 2 27 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.08, 3.13]
7 OHSS rate per couple 2 120 Odds Ratio (M-H, Fixed, 95% CI) 2.02 [0.70, 5.87]
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8 ectopic pregnancy rate per
couple
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. gonadotrophins alone versus gonadotrophins with GnRH antagonist




participants Statistical method Effect size
1 live birth rate per couple 1 80 Odds Ratio (M-H, Fixed, 95% CI) 3.04 [1.07, 8.57]
2 pregnancy rate per couple 3 299 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.83, 2.76]
3 multiple pregnancy rate per
couple
3 299 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.19, 2.45]
4 multiple pregnancy rate per
pregnancy
3 53 Odds Ratio (M-H, Fixed, 95% CI) 0.48 [0.12, 1.94]
5 miscarriage rate per couple 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 miscarriage rate per pregnancy 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 OHSS rate per couple 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 ectopic pregnancy rate per
couple
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 8. gonadotrophins alone versus gonadotrophins with anti-estrogens




participants Statistical method Effect size
1 live birth rate per couple 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 pregnancy rate per couple 1 98 Odds Ratio (M-H, Fixed, 95% CI) 3.13 [1.29, 7.58]
3 multiple pregnancy rate per
couple
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 multiple pregnancy rate per
pregnancy
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 miscarriage rate per couple 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 miscarriage rate per pregnancy 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 OHSS rate per couple 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 ectopic pregnancy rate per
couple
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 10. Different dosage regimen for gonadotrophins




participants Statistical method Effect size
1 live birth rate per couple 1 63 Odds Ratio (M-H, Fixed, 95% CI) 13.71 [1.62, 116.34]
2 pregnancy rate per couple 2 297 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.69, 1.92]
3 multiple pregnancy rate per
couple
2 297 Odds Ratio (M-H, Fixed, 95% CI) 3.11 [0.48, 20.13]
4 multiple pregnancy rate per
pregnancy
2 88 Odds Ratio (M-H, Fixed, 95% CI) 3.35 [0.46, 24.58]
5 miscarriage rate per couple 2 297 Odds Ratio (M-H, Fixed, 95% CI) 0.28 [0.08, 1.05]
6 miscarriage rate per pregnancy 2 88 Odds Ratio (M-H, Fixed, 95% CI) 0.28 [0.07, 1.09]
7 OHSS rate per couple 2 297 Odds Ratio (M-H, Fixed, 95% CI) 5.52 [1.85, 16.52]
8 ectopic pregnancy rate per
couple
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 11. Other comparisons




participants Statistical method Effect size
1 estrogens added to anti-estrogens 1 64 Odds Ratio (M-H, Fixed, 95% CI) 9.0 [1.82, 44.59]
2 aromatase inhibitors versus
gonadotrophins
1 80 Odds Ratio (M-H, Fixed, 95% CI) 1.20 [0.37, 3.95]
3 GnRH agonist in different
dosages
1 80 Odds Ratio (M-H, Fixed, 95% CI) 2.59 [1.02, 6.59]
4 phyto-estrogens added to
anti-estrogens
1 134 Odds Ratio (M-H, Fixed, 95% CI) 5.5 [1.49, 20.32]
5 tamoxifen with gonadotrophins
versus anti-estrogens
1 48 Odds Ratio (M-H, Fixed, 95% CI) 4.2 [0.98, 18.03]
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Analysis 1.1. Comparison 1 anti-estrogens versus gonadotrophins, Outcome 1 live birth rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 1 anti-estrogens versus gonadotrophins
Outcome: 1 live birth rate per couple
Study or subgroup anti-estrogens gonadotrophins Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dankert 2006 20/71 18/67 100.0 % 1.07 [ 0.51, 2.26 ]
Total (95% CI) 71 67 100.0 % 1.07 [ 0.51, 2.26 ]
Total events: 20 (anti-estrogens), 18 (gonadotrophins)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours gonadotrophi Favours anti-E2
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Analysis 1.2. Comparison 1 anti-estrogens versus gonadotrophins, Outcome 2 pregnancy rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 1 anti-estrogens versus gonadotrophins
Outcome: 2 pregnancy rate per couple
Study or subgroup Gonadotrophins Anti-estrogens Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Balasch 1994 12/50 4/50 8.9 % 3.63 [ 1.08, 12.18 ]
Dankert 2006 17/67 19/71 40.2 % 0.93 [ 0.43, 1.99 ]
Ecochard 2000 3/29 6/29 15.7 % 0.44 [ 0.10, 1.97 ]
Kamel 1995 4/28 2/26 5.2 % 2.00 [ 0.33, 11.97 ]
Karlstrom 1993 3/15 1/17 2.2 % 4.00 [ 0.37, 43.38 ]
Karlstrom 1998 8/40 4/34 10.1 % 1.88 [ 0.51, 6.88 ]
Matorras 2002 30/49 16/51 17.7 % 3.45 [ 1.51, 7.88 ]
Total (95% CI) 278 278 100.0 % 1.76 [ 1.16, 2.66 ]
Total events: 77 (Gonadotrophins), 52 (Anti-estrogens)
Heterogeneity: Chi2 = 10.40, df = 6 (P = 0.11); I2 =42%
Test for overall effect: Z = 2.68 (P = 0.0074)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours anti-E2 Favours gonadotrophn
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Analysis 1.3. Comparison 1 anti-estrogens versus gonadotrophins, Outcome 3 multiple pregnancy rate per
couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 1 anti-estrogens versus gonadotrophins
Outcome: 3 multiple pregnancy rate per couple
Study or subgroup anti-E2 gonadotrophins Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Balasch 1994 0/50 0/50 Not estimable
Dankert 2006 2/71 1/67 14.5 % 1.91 [ 0.17, 21.60 ]
Matorras 2002 2/51 6/49 85.5 % 0.29 [ 0.06, 1.53 ]
Total (95% CI) 172 166 100.0 % 0.53 [ 0.15, 1.86 ]
Total events: 4 (anti-E2), 7 (gonadotrophins)
Heterogeneity: Chi2 = 1.57, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours anti-E2 Favours gonadotr
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Analysis 1.4. Comparison 1 anti-estrogens versus gonadotrophins, Outcome 4 multiple pregnancy rate per
pregnancy.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 1 anti-estrogens versus gonadotrophins
Outcome: 4 multiple pregnancy rate per pregnancy
Study or subgroup gonadotrophins Anti-estrogens Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Balasch 1994 0/12 0/4 Not estimable
Dankert 2006 1/23 2/27 33.9 % 0.57 [ 0.05, 6.70 ]
Matorras 2002 6/30 2/16 40.2 % 1.75 [ 0.31, 9.88 ]
Nakajima 1999 0/4 1/4 26.0 % 0.26 [ 0.01, 8.52 ]
Total (95% CI) 69 51 100.0 % 0.96 [ 0.28, 3.28 ]
Total events: 7 (gonadotrophins), 5 (Anti-estrogens)
Heterogeneity: Chi2 = 1.18, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours gonadotroph Favours anti-E2
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Analysis 1.5. Comparison 1 anti-estrogens versus gonadotrophins, Outcome 5 miscarriage rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 1 anti-estrogens versus gonadotrophins
Outcome: 5 miscarriage rate per couple
Study or subgroup gonadotrophins Anti-estrogens Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Balasch 1994 1/50 2/50 15.9 % 0.49 [ 0.04, 5.58 ]
Dankert 2006 5/67 7/71 50.9 % 0.74 [ 0.22, 2.45 ]
Matorras 2002 8/49 5/51 33.2 % 1.80 [ 0.54, 5.92 ]
Total (95% CI) 166 172 100.0 % 1.05 [ 0.48, 2.29 ]
Total events: 14 (gonadotrophins), 14 (Anti-estrogens)
Heterogeneity: Chi2 = 1.49, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours gonadotrophi Favours anti-E2
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Analysis 1.6. Comparison 1 anti-estrogens versus gonadotrophins, Outcome 6 miscarriage rate per
pregnancy.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 1 anti-estrogens versus gonadotrophins
Outcome: 6 miscarriage rate per pregnancy
Study or subgroup gonadotrophins anti-estrogens Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Balasch 1994 1/12 2/4 21.3 % 0.09 [ 0.01, 1.55 ]
Dankert 2006 5/23 7/27 39.0 % 0.79 [ 0.21, 2.95 ]
Matorras 2002 8/30 5/16 37.0 % 0.80 [ 0.21, 3.03 ]
Nakajima 1999 1/4 0/4 2.7 % 3.86 [ 0.12, 126.73 ]
Total (95% CI) 69 51 100.0 % 0.73 [ 0.32, 1.67 ]
Total events: 15 (gonadotrophins), 14 (anti-estrogens)
Heterogeneity: Chi2 = 2.98, df = 3 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours gonadotroph Favours anti-E2
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Analysis 1.7. Comparison 1 anti-estrogens versus gonadotrophins, Outcome 7 OHSS rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 1 anti-estrogens versus gonadotrophins
Outcome: 7 OHSS rate per couple
Study or subgroup gonadotrophins Estrogens Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Balasch 1994 0/50 0/50 Not estimable
Matorras 2002 4/49 1/51 100.0 % 4.44 [ 0.48, 41.25 ]
Total (95% CI) 99 101 100.0 % 4.44 [ 0.48, 41.25 ]
Total events: 4 (gonadotrophins), 1 (Estrogens)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours gonadotroph Favours anti-E2
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Analysis 4.2. Comparison 4 anti-estrogens versus aromatase inhibitors, Outcome 2 pregnancy rate per
couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 4 anti-estrogens versus aromatase inhibitors
Outcome: 2 pregnancy rate per couple
Study or subgroup aromatase inhibitor anti-estrogens Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al-Fozan 2004 13/74 15/80 57.8 % 0.92 [ 0.41, 2.10 ]
El Helw 2002 5/27 3/26 12.1 % 1.74 [ 0.37, 8.18 ]
Fatemi 2003 2/7 3/8 9.7 % 0.67 [ 0.08, 5.88 ]
Ozmen 2005 4/22 3/21 12.2 % 1.33 [ 0.26, 6.83 ]
Sammour 2001 4/24 2/24 8.1 % 2.20 [ 0.36, 13.34 ]
Total (95% CI) 154 159 100.0 % 1.15 [ 0.64, 2.08 ]
Total events: 28 (aromatase inhibitor), 26 (anti-estrogens)
Heterogeneity: Chi2 = 1.32, df = 4 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 anti-estrogens versus aromatase inhibitors, Outcome 3 multiple pregnancy rate
per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 4 anti-estrogens versus aromatase inhibitors
Outcome: 3 multiple pregnancy rate per couple
Study or subgroup Aromatase inhibitors Anti-E2 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al-Fozan 2004 0/74 1/80 100.0 % 0.36 [ 0.01, 8.87 ]
Total (95% CI) 74 80 100.0 % 0.36 [ 0.01, 8.87 ]
Total events: 0 (Aromatase inhibitors), 1 (Anti-E2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours arom inhibit Favours anti-E2
Analysis 4.4. Comparison 4 anti-estrogens versus aromatase inhibitors, Outcome 4 multiple pregnancy rate
per pregnancy.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 4 anti-estrogens versus aromatase inhibitors
Outcome: 4 multiple pregnancy rate per pregnancy
Study or subgroup aromatase inhibitor anti-E2 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al-Fozan 2004 0/13 1/11 100.0 % 0.26 [ 0.01, 7.03 ]
Total (95% CI) 13 11 100.0 % 0.26 [ 0.01, 7.03 ]
Total events: 0 (aromatase inhibitor), 1 (anti-E2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 anti-estrogens versus aromatase inhibitors, Outcome 5 miscarriage rate per
couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 4 anti-estrogens versus aromatase inhibitors
Outcome: 5 miscarriage rate per couple
Study or subgroup Aromatase inhibitors Anti-E2 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al-Fozan 2004 0/74 4/80 100.0 % 0.11 [ 0.01, 2.16 ]
Total (95% CI) 74 80 100.0 % 0.11 [ 0.01, 2.16 ]
Total events: 0 (Aromatase inhibitors), 4 (Anti-E2)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 anti-estrogens versus aromatase inhibitors, Outcome 6 miscarriage rate per
pregnancy.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 4 anti-estrogens versus aromatase inhibitors
Outcome: 6 miscarriage rate per pregnancy
Study or subgroup aromatase inhibitors anti-estrogens Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al-Fozan 2004 0/13 4/11 100.0 % 0.06 [ 0.00, 1.31 ]
Total (95% CI) 13 11 100.0 % 0.06 [ 0.00, 1.31 ]
Total events: 0 (aromatase inhibitors), 4 (anti-estrogens)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 different types of gonadotrophins, Outcome 1 live birth rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 5 different types of gonadotrophins
Outcome: 1 live birth rate per couple
Study or subgroup hMG FSH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 A). hMG versus FSH
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (hMG), 0 (FSH)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 B). r-FSH versus u-FSH
Gerli 2004 0/1 0/1 Not estimable
Gerli 2004 (II) 0/1 0/1 Not estimable
Subtotal (95% CI) 2 2 Not estimable
Total events: 0 (hMG), 0 (FSH)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 5.2. Comparison 5 different types of gonadotrophins, Outcome 2 pregnancy rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 5 different types of gonadotrophins
Outcome: 2 pregnancy rate per couple
Study or subgroup hMG (or r-FSH) FSH (or u-FSH) Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 A). hMG versus FSH
Filicori 2001 6/25 5/25 14.7 % 1.26 [ 0.33, 4.84 ]
Filicori 2003 7/25 4/25 11.1 % 2.04 [ 0.51, 8.12 ]
Gerli 1993 5/15 1/17 2.4 % 8.00 [ 0.81, 78.83 ]
Gurgan 2004 5/40 21/81 47.0 % 0.41 [ 0.14, 1.18 ]
Gurgan II 2004 5/40 11/80 24.8 % 0.90 [ 0.29, 2.78 ]
Subtotal (95% CI) 145 228 100.0 % 1.02 [ 0.59, 1.75 ]
Total events: 28 (hMG (or r-FSH)), 42 (FSH (or u-FSH))
Heterogeneity: Chi2 = 7.10, df = 4 (P = 0.13); I2 =44%
Test for overall effect: Z = 0.07 (P = 0.94)
2 B). r-FSH versus u-FSH
Gerli 2004 23/88 22/82 32.1 % 0.97 [ 0.49, 1.91 ]
Gerli 2004 (II) 9/35 8/32 11.8 % 1.04 [ 0.34, 3.13 ]
Gurgan 2004 21/81 11/80 15.6 % 2.20 [ 0.98, 4.92 ]
Matorras 2000 26/45 24/46 19.1 % 1.25 [ 0.55, 2.87 ]
Pares 2002 28/55 24/61 21.3 % 1.60 [ 0.76, 3.34 ]
Subtotal (95% CI) 304 301 100.0 % 1.36 [ 0.95, 1.94 ]
Total events: 107 (hMG (or r-FSH)), 89 (FSH (or u-FSH))
Heterogeneity: Chi2 = 2.78, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
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Analysis 5.3. Comparison 5 different types of gonadotrophins, Outcome 3 multiple pregnancy rate per
couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 5 different types of gonadotrophins
Outcome: 3 multiple pregnancy rate per couple
Study or subgroup hMG (or r-FSH) FSH (or u-FSH) Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 A). hMG versus FSH
Filicori 2001 1/25 3/25 62.1 % 0.31 [ 0.03, 3.16 ]
Filicori 2003 3/25 2/25 37.9 % 1.57 [ 0.24, 10.30 ]
Subtotal (95% CI) 50 50 100.0 % 0.78 [ 0.20, 3.09 ]
Total events: 4 (hMG (or r-FSH)), 5 (FSH (or u-FSH))
Heterogeneity: Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 0.35 (P = 0.73)
2 B). r-FSH versus u-FSH
Gerli 2004 3/88 3/82 25.1 % 0.93 [ 0.18, 4.74 ]
Gerli 2004 (II) 0/35 0/32 Not estimable
Matorras 2000 4/45 7/46 52.8 % 0.54 [ 0.15, 2.00 ]
Pares 2002 4/55 3/61 22.1 % 1.52 [ 0.32, 7.10 ]
Subtotal (95% CI) 223 221 100.0 % 0.86 [ 0.37, 1.97 ]
Total events: 11 (hMG (or r-FSH)), 13 (FSH (or u-FSH))
Heterogeneity: Chi2 = 1.00, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
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Analysis 5.4. Comparison 5 different types of gonadotrophins, Outcome 4 multiple pregnancy rate per
pregnancy.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 5 different types of gonadotrophins
Outcome: 4 multiple pregnancy rate per pregnancy
Study or subgroup hMG (or r-FSH) FSH (or u-FSH) Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 A). hMG versus FSH
Filicori 2001 1/6 3/5 65.2 % 0.13 [ 0.01, 2.18 ]
Filicori 2003 3/7 2/4 34.8 % 0.75 [ 0.06, 8.83 ]
Subtotal (95% CI) 13 9 100.0 % 0.35 [ 0.06, 2.03 ]
Total events: 4 (hMG (or r-FSH)), 5 (FSH (or u-FSH))
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
2 B). r-FSH versus u-FSH
Gerli 2004 3/23 3/22 23.0 % 0.95 [ 0.17, 5.30 ]
Gerli 2004 (II) 0/9 0/8 Not estimable
Matorras 2000 4/26 7/24 53.1 % 0.44 [ 0.11, 1.76 ]
Pares 2002 4/28 3/24 23.9 % 1.17 [ 0.23, 5.82 ]
Subtotal (95% CI) 86 78 100.0 % 0.73 [ 0.30, 1.76 ]
Total events: 11 (hMG (or r-FSH)), 13 (FSH (or u-FSH))
Heterogeneity: Chi2 = 0.93, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.49)
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Analysis 5.5. Comparison 5 different types of gonadotrophins, Outcome 5 miscarriage rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 5 different types of gonadotrophins
Outcome: 5 miscarriage rate per couple
Study or subgroup hMG (or r-FSH) FSH (or u-FSH) Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 A). hMG versus FSH
Filicori 2001 1/25 1/25 50.0 % 1.00 [ 0.06, 16.93 ]
Filicori 2003 1/25 1/25 50.0 % 1.00 [ 0.06, 16.93 ]
Subtotal (95% CI) 50 50 100.0 % 1.00 [ 0.14, 7.39 ]
Total events: 2 (hMG (or r-FSH)), 2 (FSH (or u-FSH))
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
2 B). r-FSH versus u-FSH
Gerli 2004 3/88 3/82 27.7 % 0.93 [ 0.18, 4.74 ]
Gerli 2004 (II) 1/35 1/32 9.4 % 0.91 [ 0.05, 15.21 ]
Matorras 2000 7/45 3/46 23.1 % 2.64 [ 0.64, 10.94 ]
Pares 2002 5/55 5/61 39.8 % 1.12 [ 0.31, 4.10 ]
Subtotal (95% CI) 223 221 100.0 % 1.40 [ 0.64, 3.04 ]
Total events: 16 (hMG (or r-FSH)), 12 (FSH (or u-FSH))
Heterogeneity: Chi2 = 1.21, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
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Analysis 5.6. Comparison 5 different types of gonadotrophins, Outcome 6 miscarriage rate per pregnancy.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 5 different types of gonadotrophins
Outcome: 6 miscarriage rate per pregnancy
Study or subgroup hMG (or r-FSH) FSH (or u-FSH) Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 A). hMG versus FSH
Filicori 2001 1/6 1/5 45.5 % 0.80 [ 0.04, 17.20 ]
Filicori 2003 1/7 1/4 54.5 % 0.50 [ 0.02, 11.09 ]
Subtotal (95% CI) 13 9 100.0 % 0.64 [ 0.07, 5.62 ]
Total events: 2 (hMG (or r-FSH)), 2 (FSH (or u-FSH))
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
2 B). r-FSH versus u-FSH
Gerli 2004 3/23 3/22 27.1 % 0.95 [ 0.17, 5.30 ]
Gerli 2004 (II) 1/9 1/8 9.6 % 0.88 [ 0.05, 16.74 ]
Matorras 2000 7/26 3/24 23.2 % 2.58 [ 0.58, 11.42 ]
Pares 2002 5/22 5/21 40.2 % 0.94 [ 0.23, 3.87 ]
Subtotal (95% CI) 80 75 100.0 % 1.32 [ 0.58, 3.01 ]
Total events: 16 (hMG (or r-FSH)), 12 (FSH (or u-FSH))
Heterogeneity: Chi2 = 1.21, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.51)
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Analysis 5.7. Comparison 5 different types of gonadotrophins, Outcome 7 OHSS rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 5 different types of gonadotrophins
Outcome: 7 OHSS rate per couple
Study or subgroup hMG (or r-FSH) FSH (or u-FSH) Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 A). hMG versus FSH
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (hMG (or r-FSH)), 0 (FSH (or u-FSH))
Heterogeneity: not applicable
Test for overall effect: not applicable
2 B). r-FSH versus u-FSH
Pares 2002 0/55 1/61 100.0 % 0.36 [ 0.01, 9.11 ]
Subtotal (95% CI) 55 61 100.0 % 0.36 [ 0.01, 9.11 ]
Total events: 0 (hMG (or r-FSH)), 1 (FSH (or u-FSH))
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
0.1 0.2 0.5 1 2 5 10
Favour hMG or r-FSH Favours FSH or u-FSH
112Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.2. Comparison 6 gonadotrophins alone versus gonadotrophins with GnRH agonist, Outcome 2
pregnancy rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 6 gonadotrophins alone versus gonadotrophins with GnRH agonist
Outcome: 2 pregnancy rate per couple
Study or subgroup
Gonadotrophins
alone gonadotrophins+GnRHanta Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carrera 2002 9/30 5/30 14.9 % 2.14 [ 0.62, 7.39 ]
Carrera 2002 (II) 8/30 5/30 15.6 % 1.82 [ 0.52, 6.38 ]
Pattuelli 1996 27/104 16/100 51.3 % 1.84 [ 0.92, 3.68 ]
Sengoku 1994 7/46 5/45 18.2 % 1.44 [ 0.42, 4.91 ]
Total (95% CI) 210 205 100.0 % 1.81 [ 1.10, 2.97 ]
Total events: 51 (Gonadotrophins alone), 31 (gonadotrophins+GnRHanta)
Heterogeneity: Chi2 = 0.21, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 gonadotrophins alone versus gonadotrophins with GnRH agonist, Outcome 3
multiple pregnancy rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 6 gonadotrophins alone versus gonadotrophins with GnRH agonist
Outcome: 3 multiple pregnancy rate per couple
Study or subgroup Gonadotrophins+GnRHa
Gonadotrophins
alone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carrera 2002 2/30 0/30 9.3 % 5.35 [ 0.25, 116.31 ]
Carrera 2002 (II) 3/30 1/30 18.1 % 3.22 [ 0.32, 32.89 ]
Pattuelli 1996 8/100 4/104 72.6 % 2.17 [ 0.63, 7.46 ]
Total (95% CI) 160 164 100.0 % 2.66 [ 0.96, 7.35 ]
Total events: 13 (Gonadotrophins+GnRHa), 5 (Gonadotrophins alone)
Heterogeneity: Chi2 = 0.33, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours GnRHagonist Favours alone
114Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.4. Comparison 6 gonadotrophins alone versus gonadotrophins with GnRH agonist, Outcome 4
multiple pregnancy rate per pregnancy.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 6 gonadotrophins alone versus gonadotrophins with GnRH agonist
Outcome: 4 multiple pregnancy rate per pregnancy
Study or subgroup Gonadotrophins+GnRHa
gonadotrophins
alone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carrera 2002 2/9 0/5 17.2 % 3.67 [ 0.15, 92.65 ]
Carrera 2002 (II) 3/8 1/5 28.2 % 2.40 [ 0.18, 32.88 ]
Pattuelli 1996 8/16 4/27 54.6 % 5.75 [ 1.36, 24.39 ]
Total (95% CI) 33 37 100.0 % 4.45 [ 1.36, 14.55 ]
Total events: 13 (Gonadotrophins+GnRHa), 5 (gonadotrophins alone)
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.014)
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 gonadotrophins alone versus gonadotrophins with GnRH agonist, Outcome 5
miscarriage rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 6 gonadotrophins alone versus gonadotrophins with GnRH agonist
Outcome: 5 miscarriage rate per couple
Study or subgroup gonadotrophins+GnRHa
gonadotrophins
alone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carrera 2002 2/30 1/30 32.6 % 2.07 [ 0.18, 24.15 ]
Carrera 2002 (II) 1/30 2/30 67.4 % 0.48 [ 0.04, 5.63 ]
Total (95% CI) 60 60 100.0 % 1.00 [ 0.19, 5.14 ]
Total events: 3 (gonadotrophins+GnRHa), 3 (gonadotrophins alone)
Heterogeneity: Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 6.6. Comparison 6 gonadotrophins alone versus gonadotrophins with GnRH agonist, Outcome 6
miscarriage rate per pregnancy.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 6 gonadotrophins alone versus gonadotrophins with GnRH agonist
Outcome: 6 miscarriage rate per pregnancy
Study or subgroup gonadotrophins+GnRHa
Gonadotrophins
alone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carrera 2002 2/9 1/5 31.7 % 1.14 [ 0.08, 16.95 ]
Carrera 2002 (II) 1/8 2/5 68.3 % 0.21 [ 0.01, 3.37 ]
Total (95% CI) 17 10 100.0 % 0.51 [ 0.08, 3.13 ]
Total events: 3 (gonadotrophins+GnRHa), 3 (Gonadotrophins alone)
Heterogeneity: Chi2 = 0.72, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 6.7. Comparison 6 gonadotrophins alone versus gonadotrophins with GnRH agonist, Outcome 7
OHSS rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 6 gonadotrophins alone versus gonadotrophins with GnRH agonist
Outcome: 7 OHSS rate per couple
Study or subgroup Gonadotrophins+GnRHa
gonadotrophins
alone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carrera 2002 5/30 3/30 51.0 % 1.80 [ 0.39, 8.32 ]
Carrera 2002 (II) 6/30 3/30 49.0 % 2.25 [ 0.51, 9.99 ]
Total (95% CI) 60 60 100.0 % 2.02 [ 0.70, 5.87 ]
Total events: 11 (Gonadotrophins+GnRHa), 6 (gonadotrophins alone)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 gonadotrophins alone versus gonadotrophins with GnRH antagonist, Outcome
1 live birth rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 7 gonadotrophins alone versus gonadotrophins with GnRH antagonist
Outcome: 1 live birth rate per couple
Study or subgroup gonadotrophins+antag
gonadotrophins
alone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gomez 2005 15/39 7/41 100.0 % 3.04 [ 1.07, 8.57 ]
Total (95% CI) 39 41 100.0 % 3.04 [ 1.07, 8.57 ]
Total events: 15 (gonadotrophins+antag), 7 (gonadotrophins alone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 gonadotrophins alone versus gonadotrophins with GnRH antagonist, Outcome
2 pregnancy rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 7 gonadotrophins alone versus gonadotrophins with GnRH antagonist
Outcome: 2 pregnancy rate per couple
Study or subgroup gonadotrophins+antag
gonadotrophins
alone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gomez 2005 15/39 7/41 24.2 % 3.04 [ 1.07, 8.57 ]
Lambalk 2006 13/93 12/85 62.2 % 0.99 [ 0.42, 2.30 ]
Ragni 2001 3/19 3/22 13.5 % 1.19 [ 0.21, 6.72 ]
Total (95% CI) 151 148 100.0 % 1.51 [ 0.83, 2.76 ]
Total events: 31 (gonadotrophins+antag), 22 (gonadotrophins alone)
Heterogeneity: Chi2 = 2.77, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 gonadotrophins alone versus gonadotrophins with GnRH antagonist, Outcome
3 multiple pregnancy rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 7 gonadotrophins alone versus gonadotrophins with GnRH antagonist
Outcome: 3 multiple pregnancy rate per couple
Study or subgroup gonadotrophins+antag
gonadotrophins
alone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gomez 2005 1/39 0/41 8.3 % 3.23 [ 0.13, 81.79 ]
Lambalk 2006 2/93 2/85 35.9 % 0.91 [ 0.13, 6.62 ]
Ragni 2001 0/19 3/22 55.8 % 0.14 [ 0.01, 2.95 ]
Total (95% CI) 151 148 100.0 % 0.67 [ 0.19, 2.45 ]
Total events: 3 (gonadotrophins+antag), 5 (gonadotrophins alone)
Heterogeneity: Chi2 = 2.00, df = 2 (P = 0.37); I2 =0%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 gonadotrophins alone versus gonadotrophins with GnRH antagonist, Outcome
4 multiple pregnancy rate per pregnancy.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 7 gonadotrophins alone versus gonadotrophins with GnRH antagonist
Outcome: 4 multiple pregnancy rate per pregnancy
Study or subgroup Gonadotrophins+antag
gonadotrophins
alone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gomez 2005 1/15 0/7 11.1 % 1.55 [ 0.06, 42.91 ]
Lambalk 2006 2/13 2/12 32.4 % 0.91 [ 0.11, 7.72 ]
Ragni 2001 0/3 3/3 56.4 % 0.02 [ 0.00, 1.35 ]
Total (95% CI) 31 22 100.0 % 0.48 [ 0.12, 1.94 ]
Total events: 3 (Gonadotrophins+antag), 5 (gonadotrophins alone)
Heterogeneity: Chi2 = 3.00, df = 2 (P = 0.22); I2 =33%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 gonadotrophins alone versus gonadotrophins with anti-estrogens, Outcome 2
pregnancy rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 8 gonadotrophins alone versus gonadotrophins with anti-estrogens
Outcome: 2 pregnancy rate per couple
Study or subgroup gonadotroph+anti-E2
gonadotrophins
alone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ransom 1996 25/53 10/45 100.0 % 3.13 [ 1.29, 7.58 ]
Total (95% CI) 53 45 100.0 % 3.13 [ 1.29, 7.58 ]
Total events: 25 (gonadotroph+anti-E2), 10 (gonadotrophins alone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Different dosage regimen for gonadotrophins, Outcome 1 live birth rate per
couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 10 Different dosage regimen for gonadotrophins
Outcome: 1 live birth rate per couple
Study or subgroup daily dose alternate day dose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ragni 2004 9/30 1/33 100.0 % 13.71 [ 1.62, 116.34 ]
Total (95% CI) 30 33 100.0 % 13.71 [ 1.62, 116.34 ]
Total events: 9 (daily dose), 1 (alternate day dose)
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Different dosage regimen for gonadotrophins, Outcome 2 pregnancy rate per
couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 10 Different dosage regimen for gonadotrophins
Outcome: 2 pregnancy rate per couple
Study or subgroup high dose low dose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dhaliwal 2002 39/100 35/100 78.3 % 1.19 [ 0.67, 2.11 ]
Sengoku 1999 7/48 7/49 21.7 % 1.02 [ 0.33, 3.18 ]
Total (95% CI) 148 149 100.0 % 1.15 [ 0.69, 1.92 ]
Total events: 46 (high dose), 42 (low dose)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 Different dosage regimen for gonadotrophins, Outcome 3 multiple
pregnancy rate per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 10 Different dosage regimen for gonadotrophins
Outcome: 3 multiple pregnancy rate per couple
Study or subgroup high dose low dose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dhaliwal 2002 2/100 0/100 34.0 % 5.10 [ 0.24, 107.62 ]
Sengoku 1999 2/48 1/49 66.0 % 2.09 [ 0.18, 23.81 ]
Total (95% CI) 148 149 100.0 % 3.11 [ 0.48, 20.13 ]
Total events: 4 (high dose), 1 (low dose)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 10.4. Comparison 10 Different dosage regimen for gonadotrophins, Outcome 4 multiple
pregnancy rate per pregnancy.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 10 Different dosage regimen for gonadotrophins
Outcome: 4 multiple pregnancy rate per pregnancy
Study or subgroup High dose low dose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dhaliwal 2002 2/39 0/35 40.9 % 4.73 [ 0.22, 102.05 ]
Sengoku 1999 2/7 1/7 59.1 % 2.40 [ 0.16, 34.93 ]
Total (95% CI) 46 42 100.0 % 3.35 [ 0.46, 24.58 ]
Total events: 4 (High dose), 1 (low dose)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 10.5. Comparison 10 Different dosage regimen for gonadotrophins, Outcome 5 miscarriage rate
per couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 10 Different dosage regimen for gonadotrophins
Outcome: 5 miscarriage rate per couple
Study or subgroup high dose low dose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dhaliwal 2002 2/100 9/100 89.9 % 0.21 [ 0.04, 0.98 ]
Sengoku 1999 1/49 1/48 10.1 % 0.98 [ 0.06, 16.12 ]
Total (95% CI) 149 148 100.0 % 0.28 [ 0.08, 1.05 ]
Total events: 3 (high dose), 10 (low dose)
Heterogeneity: Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
Test for subgroup differences: Not applicable
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Analysis 10.6. Comparison 10 Different dosage regimen for gonadotrophins, Outcome 6 miscarriage rate
per pregnancy.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 10 Different dosage regimen for gonadotrophins
Outcome: 6 miscarriage rate per pregnancy
Study or subgroup high dose low dose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dhaliwal 2002 2/35 9/39 90.4 % 0.20 [ 0.04, 1.01 ]
Sengoku 1999 1/7 1/7 9.6 % 1.00 [ 0.05, 19.96 ]
Total (95% CI) 42 46 100.0 % 0.28 [ 0.07, 1.09 ]
Total events: 3 (high dose), 10 (low dose)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Not applicable
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Analysis 10.7. Comparison 10 Different dosage regimen for gonadotrophins, Outcome 7 OHSS rate per
couple.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 10 Different dosage regimen for gonadotrophins
Outcome: 7 OHSS rate per couple
Study or subgroup high dose low dose Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dhaliwal 2002 6/100 0/100 13.9 % 13.83 [ 0.77, 248.79 ]
Sengoku 1999 13/48 4/49 86.1 % 4.18 [ 1.25, 13.94 ]
Total (95% CI) 148 149 100.0 % 5.52 [ 1.85, 16.52 ]
Total events: 19 (high dose), 4 (low dose)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Other comparisons, Outcome 1 estrogens added to anti-estrogens.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 11 Other comparisons
Outcome: 1 estrogens added to anti-estrogens
Study or subgroup CC+E2 CC alone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gerli 2000 12/32 2/32 100.0 % 9.00 [ 1.82, 44.59 ]
Total (95% CI) 32 32 100.0 % 9.00 [ 1.82, 44.59 ]
Total events: 12 (CC+E2), 2 (CC alone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.0071)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 Other comparisons, Outcome 2 aromatase inhibitors versus gonadotrophins.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 11 Other comparisons
Outcome: 2 aromatase inhibitors versus gonadotrophins
Study or subgroup letrozole hMG Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jamal 2005 7/40 6/40 100.0 % 1.20 [ 0.37, 3.95 ]
Total (95% CI) 40 40 100.0 % 1.20 [ 0.37, 3.95 ]
Total events: 7 (letrozole), 6 (hMG)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Other comparisons, Outcome 3 GnRH agonist in different dosages.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 11 Other comparisons
Outcome: 3 GnRH agonist in different dosages
Study or subgroup ultralong protocol long protocol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kim 1996 19/39 11/41 100.0 % 2.59 [ 1.02, 6.59 ]
Total (95% CI) 39 41 100.0 % 2.59 [ 1.02, 6.59 ]
Total events: 19 (ultralong protocol), 11 (long protocol)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Not applicable
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Analysis 11.4. Comparison 11 Other comparisons, Outcome 4 phyto-estrogens added to anti-estrogens.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 11 Other comparisons
Outcome: 4 phyto-estrogens added to anti-estrogens
Study or subgroup phyto-E2+ CC CC alone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Unfer 2004 13/65 3/69 100.0 % 5.50 [ 1.49, 20.32 ]
Total (95% CI) 65 69 100.0 % 5.50 [ 1.49, 20.32 ]
Total events: 13 (phyto-E2+ CC), 3 (CC alone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.011)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours CC alone Favours phyto-E2+CC
131Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine
insemination (IUI) in women with subfertility (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 11.5. Comparison 11 Other comparisons, Outcome 5 tamoxifen with gonadotrophins versus anti-
estrogens.
Review: Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with
subfertility
Comparison: 11 Other comparisons
Outcome: 5 tamoxifen with gonadotrophins versus anti-estrogens
Study or subgroup tamoxifen+gonadotrop CC Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wang 2004 6/16 4/32 100.0 % 4.20 [ 0.98, 18.03 ]
Total (95% CI) 16 32 100.0 % 4.20 [ 0.98, 18.03 ]
Total events: 6 (tamoxifen+gonadotrop), 4 (CC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. studies awaiting assessment
Studies Reason for awaiting
Bekuretsion 1999 Abstract from congress meeting; At the weekend couples were instructed to have intercourse. If data of IUI cycles
can be extracted this data could be included
Colombi 1996 Abstract from congress meeting; It is stated that study prospective and randomised but the group size differs too
much 233 versus 192 cycles
Fernandez 2001 Abstract from congress meeting; 5.6% of the cycles were followed by timed intercourse. If data from IUI cycles
can be extracted this can be included
Karande 1995 Trial stated randomisation method for insemination technique. It is not clear whether randomisation is used for
ovarian stimulation
Karlstrom 2000 118 couples received DIPI and 33 couples IUI. At the weekends couples were instructed to have intercourse. If
data of IUI cycles is available these couples with one insemination could be included
Karlstrom 2002 Abstract from congress meeting; not clear which couple received IUI or intercourse
Kotecki 2005 This trial is stated as randomised but the treatment groups have totally different sizes
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Table 2. study quality
study concealment of al-
loc
randomisation blinding intention to treat power calculation
Balasch 1994 unclear stated without fur-
ther description
no not stated no
Dankert 2005 unclear computer generated
list
no not stated no
Ecochard 2000 adequate random number ta-
ble
no yes yes
Kamel 1995 unclear stated without fur-
ther description
no not stated no
Karlstrom 1993 unclear stated without fur-
ther description
no not stated no
Karlstrom 1998 unclear stated without fur-
ther description
no not stated no
Nakajima 1999 inadequate open randomized list no not stated no
Matorras 2002 unclear computer generated
random list
no not stated no
Al-Fozan 2004 unclear computer generated
random table
no not stated no
El Helw 2002 unclear stated without fur-
ther description
no not stated no
Fatemi 2003 unclear random number ta-
ble
no not stated no
Ozmen 2005 unclear stated without fur-
ther description
no not stated no
Sammour 2001 unclear stated without fur-
ther description
no not stated no
Filicori 2001 unclear stated without fur-
ther description
no not stated no
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Table 2. study quality (Continued)
Filicori 2003 unclear stated without fur-
ther description
no not stated no
Gerli 1993 unclear stated without fur-
ther description
no not stated no
Gerli 2004 adequate randomisation table no yes no
Gerli 2004 II adequate randomsation table no yes no
Matorras 2000 adequate computer generated
list
single-blinded yes no
Pares 2002 unclear stated without fur-
ther description
no yes no
Demirol 2002 adequate computer generated
random number ta-
ble
no not stated no
Gurgan 2004 unclear stated without fur-
ther description
no not stated no
Carrera 2002 unclear numeric list no not stated no
Carrera 2002 unclear stated without fur-
ther description
no not stated no
Dodson 1991 unclear stated without fur-
ther description
no not stated yes
Pattuelli 1996 unclear stated without fur-
ther description
no not stated no
Sengoku 1994 unclear stated without fur-
ther description
no not stated no
Gomez 2005 unclear computer generated
list
no not stated no
Lambalk 2006 unclear stated without fur-
ther description
double-blinded yes yes
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Table 2. study quality (Continued)
Ragni 2001 unclear computer generated
list
no not stated no
Scheiber 2003 unclear stated without fur-
ther description
no not stated no
Williams 2004 adequate computer generated
list
no not stated yes
Ransom 1996 unclear random number ta-
ble
no not stated no
Al Fadhli 2005 unclear stated without fur-
ther description
no not stated no
Dhaliwal 2002 unclear computer generated
random number ta-
ble
no not stated no
Hughes 1998 unclear central randomisa-
tion scheme
no not stated yes
Ragni 2004 adequate blocked randomisa-
tion list
no not stated yes
Sengoku 1999 adequate random number ta-
ble
no not stated yes
Gerli 2000 unclear stated without fur-
ther description
no not stated no
Jamal 2005 unclear stated without fur-
ther description
no not stated no
Kim 1996 unclear blocked randomisa-
tion design
no not stated no
Unfer 2004 unclear stated without fur-
ther description
no not stated no
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Table 2. study quality (Continued)
Wang 2004 unclear stated without fur-
ther description
no not stated no
WH A T ’ S N E W
Last assessed as up-to-date: 23 January 2007.
Date Event Description
12 November 2010 Amended The results of comparison 6.2 and 6.3 have been edited in the text and data/analysis section
H I S T O R Y
Protocol first published: Issue 3, 2005
Review first published: Issue 2, 2007
Date Event Description
24 January 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
AEP Cantineau took lead in developing the protocol.
MJ Heineman and BJ Cohlen commented drafts of the protocol.
D E C L A R A T I O N S O F I N T E R E S T
Recently, we started a large randomised controlled trial comparing recFSH with a GnRH antagonist with recFSH alone. This is an
investigators-initiated trial.
Medication used in this trial has been supplied by Serono B.V. only. Serono B.V. is unable to interfere with the results of this RCT
and they have had no influence on this Cochrane review. In conclusion, all three authors have involvement in primary research in the
subject area of our review, but no personal financial support has been gained.
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• MDSG, New Zealand.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Estrogen Antagonists [therapeutic use]; Gonadotropin-Releasing Hormone [∗agonists; ∗antagonists & inhibitors]; Gonadotropins
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